

Appendix 3: Code groups from ICPC-2 and ICPC-2 PLUS

Table A3.1: Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
REASONS FOR ENCOUNTER AND PROBLEMS MANAGED			
Abdominal pain	D01		Pain/cramps; abdominal general
	D06		Pain; abdominal localised; other
Abnormal test results	A91		Abnormal result investigations NOS
	B84		Unexplained abnormal white cells
	U98		Abnormal urine test NOS
	X86		Abnormal cervix smear
Anaemia	B80		Iron deficiency anaemia
	B81		Anaemia; vitamin B12/folate deficiency
	B82		Anaemia; other/unspecified
Anxiety	P01		Feeling anxious/nervous/tense
	P74		Anxiety disorder/anxiety state
Arthritis		L70009	Arthritis; pyogenic
		L70010	Arthritis; viral
		L70021	Arthritis; septic
		L81003	Arthritis; traumatic
		L83010	Arthritis; spine cervical
		L84003	Arthritis; spine
		L84023	Arthritis; spine thoracic
		L84024	Arthritis; spine lumbar
		L84025	Arthritis; lumbosacral
		L84026	Arthritis; sacroiliac
		L89004	Arthritis; hip
		L90004	Arthritis; knee
		L91007	Arthritis; degenerative
		L91009	Arthritis
		L91010	Arthritis; acute
		L91011	Arthritis; allergic
		L91012	Polyarthritis
		L91013	Arthritis; hand/finger(s)
		L91014	Arthritis; wrist
	L92006	Arthritis; shoulder	
	S91002	Arthritis; psoriatic	
	T99063	Arthritis; crystal (excl. gout)	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label	
Reasons for encounter and problems managed (continued)				
Back complaint	L02		Back symptom/complaint	
	L03		Low back symptom/complaint	
	L86		Back syndrome with radiating pain	
Check-up—all	–30		Medical examination/health evaluation, complete	
	–31		Medical examination/health evaluation, partial	
	X37		Pap smear	
Check-up—ICPC chapter	A30; A31		General	
	B30; B31		Blood	
	D30; D31		Digestive	
	F30; F31		Eye	
	H30; H31		Ear	
	K30; K31		Cardiovascular	
	L30; L31		Musculoskeletal	
	N30; N31		Neurological	
	P30; P31		Psychological	
	R30; R31		Respiratory	
	S30; S31		Skin	
	T30; T31		Endocrine	
	U30; U31		Urology	
	W30; W31		Prenatal/postnatal	
	X30; X31; X37		Female genital	
Y30; Y31		Male genital		
Z30; Z31		Social		
Depression	P03		Feeling depressed	
	P76		Depressive disorder	
Diabetes—non-gestational	T89		Diabetes; insulin-dependent	
	T90		Diabetes; non-insulin-dependent	
Diabetes—all	T89		Diabetes; insulin-dependent	
	T90		Diabetes; non-insulin-dependent	
	W85		Gestational diabetes	
Fracture	L72		Fracture; radius/ulna	
	L73		Fracture; tibia/fibula	
	L74		Fracture; hand/foot bone	
	L75		Fracture; femur	
	L76		Fracture; other	
		L84019		Fracture; compression; spine
		L99017		Fracture; non-union

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label	
Reasons for encounter and problems managed (continued)				
Fracture (continued)		L99018	Fracture; pathological	
		L99019	Fracture; malunion	
		L99095	Fracture; stress	
		N54005	Decompression; fracture; skull	
		N80012	Fracture; skull (base)	
		N80013	Fracture; skull	
		N80014	Injury; head; fracture	
Hypertension/high BP (RFEs)	K85		Elevated blood pressure (without hypertension)	
	K86		Hypertension; uncomplicated	
	K87		Hypertension; complicated	
		W81002	Hypertension; pre-eclamptic	
		W81003	Hypertension in pregnancy	
Hypertension (problems)	K86		Hypertension; uncomplicated	
	K87		Hypertension; complicated	
		W81002	Hypertension; pre-eclamptic	
		W81003	Hypertension in pregnancy	
Immunisation	A44		Preventive immunisation/medication; general/unspecified	
	D44		Preventive immunisation/medication; digestive	
	N44		Preventive immunisation/medication; neurological	
	R44		Preventive immunisation/medication; respiratory	
Ischaemic heart disease	K74		Ischaemic heart disease with angina	
	K76		Ischaemic heart disease without angina	
Lipid disorders	T93		Lipid disorder	
		T99075	Lipodystrophy	
Menstrual problems	X02		Pain; menstrual	
	X03		Pain; intermenstrual	
	X05		Menstruation; absent/scanty	
	X06		Menstruation; excessive	
	X07		Menstruation; irregular/frequent	
	X08		Intermenstrual bleeding	
	X09		Premenstrual symptom/complaint	
	X10		Postponement of menstruation	
	Oral contraception	W10		Contraception; postcoital
		W11		Contraception; oral
W50			Medication; reproductive system	
Osteoarthritis		L83011	Osteoarthritis; spine; cervical	
		L84004	Osteoarthritis; spine	
		L84009	Osteoarthritis; spine; thoracic	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Osteoarthritis (continued)		L84010	Osteoarthritis; spine; lumbar
		L84011	Osteoarthritis; lumbosacral
		L84012	Osteoarthritis; sacroiliac
		L89001	Osteoarthritis; hip
		L90001	Osteoarthritis; knee
		L91001	Osteoarthritis; degenerative
		L91003	Osteoarthritis
		L91008	Heberdens nodes
		L91015	Osteoarthritis; wrist
	L92007	Osteoarthritis; shoulder	
Pregnancy	W01		Question of pregnancy
	W78		Pregnancy
	W79		Unwanted pregnancy
Prescription	-50		Medication prescription/request/renewal/injection
Rash	S06		Rash; localised
	S07		Rash generalised
Rheumatoid arthritis	L88		Rheumatoid/seropositive arthritis
Sprain/strain		L19014	Strain; muscle(s)
		L77	Sprain/strain; ankle
		L78	Sprain/strain; knee
		L79	Sprain/strain; joint NOS
		L83023	Sprain; neck
		L83024	Strain; neck
		L84020	Sprain; back
		L84021	Strain; back
Swelling (skin)	S04		Lump/swelling;localised
	S05		Lump/swelling;generalised
Test results	-60		Results tests/procedures
	-61		Results examination/test/record/letter other provider
Tonsillitis	R76		Tonsillitis; acute
	R90		Hypertrophy; tonsils/adenoids
Urinary tract infection	U70		Pyelonephritis/pyelitis
	U71		Cystitis/urinary infection other

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
CLINICAL TREATMENTS		
Advice/education	A45002	Advice/education
	B45002	Advice/education; blood
	D45002	Advice/education; digestive
	F45002	Advice/education; eye
	H45002	Advice/education; ear
	K45002	Advice/education; cardiovascular
	L45002	Advice/education; musculoskeletal
	N45002	Advice/education; neurological
	P45001	Advice/education; psychological
	R45002	Advice/education; respiratory
	S45002	Advice/education; skin
	T45002	Advice/education; endocrine/metabolic
	U45002	Advice/education; urology
	W45004	Advice/education; reproductive
	X45002	Advice/education; genital; female
	Y45002	Advice/education; genital; male
	Z45002	Advice/education; social
Advice/education—medication	A45015	Advice/education; medication
	A48003	Review; medication
	A48005	Increased; drug dosage
	A48006	Decreased; drug dosage
	A48007	Change (in); drug dosage
	A48008	Stop medication
	A48009	Recommend medication (not new)
	A48010	Change (in); medication
	A48011	Medication; request; refusal
	Advice/education—treatment	A45016
A45019		Advice; time off work
A45020		Advice; rest/fluids
A45021		Advice; naturopathic treatment
A48004		Review; treatment
L45004		Advice/education; RICE
T45004		Advice/education; diabetes
T45009		Advice; home glucose monitoring
Counselling/advice—alcohol	P45005	Advice/education; alcohol
	P58009	Counselling; alcohol

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Clinical treatments (continued)		
Counselling/advice—exercise	A45004	Advice/education; exercise
	A58005	Counselling; exercise
Counselling/advice—health/body	A45005	Advice/education; health
	A45009	Health promotion
	A45010	Information; health
	A45011	Health promotion; injury
	A45018	Advice/education; body
	A45026	Advice/education; hygiene
	A58006	Counselling; health
	A98001	Health maintenance
Counselling/advice—lifestyle	P45008	Advice/education; lifestyle
	P58012	Counselling; lifestyle
Counselling/advice—nutrition/weight	A45006	Advice/education; diet
	T45005	Advice/education; nutritional
	T45007	Advice/education; weight management
	T58002	Counselling; weight management
Counselling/advice—prevention	A45025	Advice/education; immunisation
	A58007	Counselling; prevention
	X45004	Advice/education; breast self exam
	Z45005	Advice/education; environment
Counselling/advice—smoking	P45004	Advice/education; smoking
	P58008	Counselling; smoking
Counselling—problem	A58002	Counselling; problem
	A58003	Counselling; individual
	B58001	Counselling; problem; blood
	D58001	Counselling; problem; digestive
	F58001	Counselling; problem; eye
	H58001	Counselling; problem; ear
	K58001	Counselling; problem; cardiovascular
	L58001	Counselling; problem; musculoskeletal
	N58001	Counselling; problem; neurological
	R58001	Counselling; problem; respiratory
	S58001	Counselling; problem; skin
	T58001	Counselling; problem; endocrine/metabolic
	U58001	Counselling; problem; urology
	W58003	Counselling; problem; reproductive
	X58001	Counselling; problem; genital; female
	X58003	Counselling; sexual; physical; female

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Clinical treatments (continued)		
Counselling—problem (continued)	Y58001	Counselling; problem; genital; male
	Y58003	Counselling; sexual; physical; male
Counselling—psychological	Z58002	Counselling; problem; social
	P45013	Anger management
	P58001	Counselling; psychiatric
	P58002	Psychotherapy
	P58004	Counselling; psychological
	P58005	Counselling; sexual; psychological
	P58006	Counselling; individual; psychological
	P58007	Counselling; bereavement
	P58013	Counselling; anger
	P58014	Counselling; self-esteem
	P58015	Counselling; assertiveness
	P58018	Therapy; group
	P58019	Cognitive behavioural therapy
	P58022	Counselling; body image
	Family planning	A98002
A98003		Counselling; genetic male
W14002		Family planning; female
W45006		Advice/education; preconceptual
W45007		Advice/education; contraception; female
W45008		Advice/education; family planning; female
W58001		Counselling; abortion
W58005		Counselling; terminate pregnancy
W58007		Counselling; preconceptual
W58012		Counselling; sterilisation; female
W58013		Counselling; family planning; female
Y14001		Family planning; male
Y45006		Advice/education; family planning; male
Y45007		Advice/education; contraception; female
Y58005		Counselling; sterilisation; male
Y58006	Counselling; family planning; male	
Observe/wait	A45001	Observe/wait
	B45001	Observe/wait; blood
	D45001	Observe/wait; digestive
	F45001	Observe/wait; eye
	H45001	Observe/wait; ear
	K45001	Observe/wait; cardiovascular
	L45001	Observe/wait; musculoskeletal

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2/ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Clinical treatments (continued)		
Observe/wait (continued)	N45001	Observe/wait; neurological
	P45002	Observe/wait; psychological
	R45001	Observe/wait; respiratory
	S45001	Observe/wait; skin
	T45001	Observe/wait; endocr/metabol
	U45001	Observe/wait; urology
	W45003	Observe/wait; reproductive
	X45001	Observe/wait; genital; female
	Y45001	Observe/wait; genital; male
Z45001	Observe/wait; social	
Other admin/document	-62 (excluding sickness certificate A62008 and A62014)	
Reassurance, support	A58010	Reassurance/support
Sickness certificate	A62008	Admin; certificate; sickness
	A62014	Admin; certificate; workers' compensation
PROCEDURES		
Incision/drainage/flushing/aspiration/ removal body fluid	-51	
Excision/removal tissue/biopsy/ destruction/debridement/cauterisation	-52	
Repair/fixation-suture/cast/prosthetic device (apply/remove)	-54	
Local injection/infiltration	-55	
Dressing/pressure/compression/tamponade	-56	
Physical medicine/rehabilitation	-57	
Other procedures/minor surgery NEC	-59	
CLINICAL MEASUREMENTS		
Electrical tracings	-42	
Other preventive procedures/high-risk medication, condition	-49	
Pap smear	X37001	Pap smear
	X37003	Test; cytology; genital; female
	X37004	Vault smear
	X37005	Pap smear; thin prep
Physical function test	-39	
Urine test	A35001	Test; urine
	A35002	Urinalysis
	B35001	Test; urine; blood
	D35001	Test; urine; digestive

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2/ICPC-2 PLUS code	ICPC-2/ICPC-2 PLUS label
Clinical measurements (continued)		
Urine test (continued)	P35001	Test; urine; psychological
	T35001	Test; urine; endocrine/metabolic
	U35002	Test; urine; urology
	W35001	Test; urine; reproductive
	Y35001	Test; urine; genital; male
REFERRALS		
Allied health services	-66	Referral to other provider/nurse/therapist/ social worker
	-68 excluding A68011; Z68003;Z68004; Z68007 and Z68008	Other referrals NEC
	Z67002	Referral; respite care
Specialist	-67 excluding A67010; A67011; A67015; P67005 and Z67002	Referral to physician/specialist/clinic/hospital
	A68009	Referral; oncologist
Emergency department	A67011	Referral; A & E
Hospital	A67010	Referral; hospital
	A67015	Referral; hospice
	P67005	Referral; hospital; psychiatrist
Other referrals	A68011	Referral
	Z68003	Referral; financial/legal services
	Z68004	Referral; police
	Z68007	Referral; women's shelter
	Z68008	Referral;Centrelink
PATHOLOGY TEST ORDERS		
Chemistry		
Amylase	D34004	Test; amylase
B12	B34015	Test; B12
	D34009	Test; Schillings
	A34005	Test; C reactive protein
Calcium/phosphate	A34006	Test; calcium
	A34013	Test; phosphate
	A34024	Test; calcium phosphate
Cardiac enzymes	D34005	Test; aspartate aminotransferas
	K34003	Test; cardiac enzymes
	K34004	Test; creatine kinase
Chemistry; other	A33023	Test; alpha fetoprotein
	A33026	Test; cancer antigen 125
	A33027	Test; cancer antigen 15.3

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Chemistry; other (continued)	A33028	Test; cancer antigen 19.9
	A33029	Test; carcinoembryonic antigen
	A33041	Test; cancer antigen
	A34015	Test; protein
	A34018	Vitamin assay
	A34019	Test; lead
	A34020	Test; blood gas analysis
	A34022	Test; mineral
	A34023	Test; zinc
	A34025	Test; DHEAS
	A34030	Test; biochemistry
	A34031	Test; blood alcohol
	A34032	Test; prolactin
	A34033	Test; testosterone
	A34037	Test; Glutathione S-transferase
	A34038	Test; magnesium
	A35004	Test; urine sodium
	A35007	Test; urine; albumin
	A35008	Test; albumin creatine ratio
	B34023	Test; transferrin
	D34002	Test; alanine aminotransferase
	D35002	Test; 5-HIAA
	K34001	Test; blood; digitalis
	K34006	Test; amino acids
	K34007	Test; troponin
	N34001	Test; blood; phenylhydantoin
	P34003	Test; methadone
	T34018	Test; androgens
	T34019	Test; insulin
	T34021	Test; C peptide
	T34029	Test; aldosterone
	T34030	Test; parathyroid hormone
	T34035	Test; lipase
	T35002	Test; catecholamines
	W38002	Amniocentesis

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Drug screen	A34002	Drug assay
	A34026	Blood drug screen
	A34027	Blood screen
	A35003	Drug screen
	A35005	Urine drug screen
	K34005	Test; digoxin
	N34003	Test; phenytoin
	N34004	Test; valproate
	N34005	Test; carbamazepine
	P34002	Test; lithium
EUC	A34007	Test; chloride
	A34008	Test; electrolytes
	A34010	Test; EUC
	A34014	Test; potassium
	A34017	Test; sodium
	A34029	Test; U&E
	A34034	Test; E&C
	U34002	Test; creatinine
	U34003	Test; urea
	HbA1c	T34010
T34017		Test; fructosamine
T34022		Test; HBA1
Ferritin	B34016	Test; ferritin
	B34019	Test; iron studies
Folic acid	B34017	Test; folic acid
	B34024	Test; folate
Glucose/tolerance	T34005	Test; glucose
	T34009	Test; glucose tolerance
	T34023	Test; glucose (fasting/random)
	T34025	Test; glucose; fasting
	T34026	Test; glucose; random
Hormone assay	A34003	Hormone assay
	D33015	Test; Anti gliadin antibody
	T34007	Test; cortisol
	T34034	Test; ACTH
	W34005	Test; HCG
	W34006	Test; B HCG level (titre/quant)
	X34002	Test; LH

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Hormone assay (continued)	X34003	Test; progesterone
	X34004	Test; oestradiol
	X34005	Test; FSH
	X34006	Test; SHBG; female
	X34007	Test; free androgen index; female
	Y34004	Test; SHBG; male
	Y34005	Test; free androgen index; male
Lactose intolerance	D38002	Test; lactose intolerance
Lipids	T34001	Check up; cholesterol
	T34004	Test; lipids profile
	T34006	Test; cholesterol
	T34011	Test; cholesterol HDL
	T34013	Test; cholesterol LDL
	T34016	Test; triglycerides
	T34020	Test; free fatty acids
	T34024	Test; chol/trig
Liver function	A34004	Test; albumin
	D34003	Test; alkaline phosphatase
	D34006	Test; bilirubin
	D34007	Test; gGT
	D34008	Test; liver function
	T34012	Test; LDH
Multi-biochemical analysis	A34012	Test; multi-biochemical analysis
	A34021	Test; E & LFT
Prostate specific antigen	Y34002	Test; acid phosphatase
	Y34003	Test; prostate specific antigen
Thyroid function	T34015	Test; thyroid function
	T34027	Test; thyroxine
	T34028	Test; tsh
Urate/uric acid	U34004	Test; urate/uric acid
Cytopathology		
Cytology	A37002	Test; cytology
	B37003	Test; cytology; blood
	D37002	Test; cytology; digestive
	F37002	Test; cytology; eye
	H37002	Test; cytology; ear
	K37002	Test; cytology; cardiovascular

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Pathology test orders (continued)			
Cytology (continued)	L37002	Test; cytology; musculoskeletal	
	N37002	Test; cytology; neurological	
	R37002	Test; cytology; respiratory	
	R37003	Test; sputum cytology	
	S37002	Test; cytology; skin	
	T37002	Test; cytology; endocr/metabol	
	U37002	Test; cytology; urology	
	W37002	Test; cytology; reproduction	
	Y37002	Test; cytology; genital; male	
	Pap smear	X37001	Pap smear
X37003		Test; cytology; genital; female	
X37004		Vault smear	
Haematology			
Blood grouping & typing	B33001	Test; Coombs	
	B33002	Test; blood grouping & typing	
	B33009	Test; blood group	
	B33013	Test; blood; cross match	
Blood; other	A33042	Test; lymphocyte type & count	
	A34035	Test; blood film	
	A34036	Test; blood thick film	
	B33003	RH; antibody titer	
	B34005	Test; blood; platelets	
	B34007	Test; blood; sickle cell	
	B34021	Test; reticulocyte count	
	B34031	Test; haemoglobin epg	
	B34032	Test; packed cell volume	
	B34033	Test; blood; blood	
	B37001	Exam; bone marrow	
	Coagulation	B34003	Test; coagulation time
		B34006	Test; part thromboplastin time
		B34009	Test; prothrombin time
B34014		Test; APTT	
B34022		Test; thrombin time	
B34025		Test; INR	
B34026		Test; fibrinogen	
B34028		Test; bleeding time	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Coagulation (continued)	B34029	Test; coagulation screen
	K34008	Test; D-Dimer
ESR	A34009	Test; ESR
Full blood count	A34011	Test; full blood count
Haemoglobin	B34018	Test; haemoglobin
Histopathology		
Histology; skin	S37001	Test; histopathology; skin
Histology; other	A37001	Test; histopathology
	B37002	Test; histopathology; blood
	D37001	Test; histopathology; digestive
	F37001	Test; histopathology; eye
	H37001	Test; histopathology; ear
	K37001	Test; histopathology; cardiovas
	L37001	Test; histopathology; musculosk
	N37001	Test; histopathology; neuro
	R37001	Test; histopathology; respirat
	T37001	Test; histopathology; endo/meta
	U37001	Test; histopathology; urology
	W37001	Test; histopathology; reproduct
	X37002	Test; histopathology; genital; female
	Y37001	Test; histopathology; genital; male
Immunology		
Anti-nuclear antibodies	L33004	Test; anti-nuclear antibodies
Immunology; other	A32001	Test; sensitivity
	A33005	Test; immunology
	A33011	Test; HLA
	A33024	Test; bone marrow surface mark
	A33025	Test; serum electrophoresis
	A33051	Test; immune status
	A33052	Test; skin patch
	A38004	Test; DNA
	B33005	Test; immunology; blood
	B33007	Test; immunoglobulins
	B33011	Test; IgE
	B34027	Test; FBC for surface markers
	B34030	Test; intrinsic factor
	D32001	Test; sensitivity; digestive

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Immunology; other (continued)	D33004	Test; immunology; digestive
	D33014	Test; endomysial antibody
	D33028	Test; mitochondrial antibodies
	F33002	Test; immunology; eye
	H33002	Test; immunology; ear
	K33002	Test; immunology; cardiovascular
	K33003	Test; ANCA
	L33003	Test; immunology; musculoskel
	L34001	Test; lupus erythemat; cell prep
	N33002	Test; immunology; neurological
	R32004	Test; sensitivity; respiratory
	R33004	Test; immunology; respiratory
	S32001	Test; sensitivity; skin
	S33002	Test; immunology; skin
	T33002	Test; immunology; endoc/metabol
	U33003	Test; immunology; urology
	W33007	Test; immunology; reproductive
	X33002	Test; immunology; genital; female
	Y33002	Test; immunology; genital; male
RAST	A34016	Test; RAST
Rheumatoid factor	L33001	Test; rheumatoid factor
Infertility/pregnancy	W33001	Test; urine; pregnancy
	W33002	Test; pregnancy
	W34002	Test; blood; pregnancy
	W34003	Test; antenatal
	W34007	Test; pregnancy screen
	W35003	Test; urine; HCG
	Y38002	Test; sperm count
	Y38003	Test; semen examination
Microbiology		
Antibody	A33003	Test; antibody
Cervical swab	X33004	Test; cervical swab M&C
Chlamydia	A33006	Test; chlamydia
	A33034	Test; chlamydia direct immunofl
	X33006	Test; viral culture; genital; female
Ear swab and C&S	H33003	Test; ear swab M&C

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Faeces MC&S	D33002	Stool(s); culture
	D33008	Test; faeces M&C
	D36001	Test; faeces; cyst/ova/parasite
Fungal ID/sensitivity	A33008	Test; fungal ID/sensitivity
	A33030	Test; skin scraping fungal M&C
Hepatitis serology	D33005	Test; hepatitis A serology
	D33006	Test; hepatitis B serology
	D33007	Test; hepatitis C serology
	D33013	Test; hepatitis serology
	D33018	Test; hepatitis A antibody
	D33019	Test; hepatitis B antibody
	D33020	Test; hepatitis D antibody
	D33021	Test; hepatitis E antibody
	D33022	Test; hepatitis A antigen
	D33023	Test; hepatitis C antigen
	D33024	Test; hepatitis D antigen
	D33025	Test; hepatitis E antigen
	D33026	Test; hepatitis antibody
	D33027	Test; hepatitis antigen
	HIV	A33021
B33006		Test; HIV
B33008		Test; AIDS screen
B33012		Test; HIV viral load
H pylori	D33009	Test; H Pylori
Microbiology; other	A33004	Test; microbiology
	A33007	Test; culture and sensitivity
	A33012	Test; mycoplasma serology
	A33013	Test; parvovirus serology
	A33015	Test; Barmah forest virus
	A33016	Test; Antistreptolysin O Titre
	A33017	Test; herpes simplex culture
	A33019	Test; herpes simplex serology
	A33020	Test; toxoplasmosis serology
	A33033	Test; swab M&C
	A33035	Test; serology
A33036	Antibodies screen	
A33038	Test; rapid plasma regain	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Microbiology; other (continued)	A33039	Test; viral swab M&C
	A33040	Test; viral serology
	A33043	Test; HPV
	A33044	Test; Brucella
	A33045	Test; fungal M&C
	A33046	Test; measles virus antibodies
	A33047	Test; Rickettsial serology
	A33053	Test; Bartonella
	A33054	Test; MC&S
	A34028	Test; blood culture
	A34039	Test; Q fever
	B33004	Test; microbiology; blood
	B33010	Test; serum immunoglobulins
	D33003	Test; microbiology; digestive
	D33010	Test; hepatitis D serology
	D33011	Test; hepatitis E serology
	D33012	Test; rotavirus
	D33016	Test; hepatitis C antibody
	D33017	Test; hepatitis B antigen
	F33001	Test; microbiology; eye
	F33003	Test; eye swab M&C
	H33001	Test; microbiology; ear
	K33001	Test; microbiology; cardiovascul
	L33002	Test; microbiology; musculoskel
	N33001	Test; microbiology; neurological
	R33001	Culture; tuberculosis
	R33002	Culture; throat
	R33003	Test; microbiology; respiratory
	R33009	Test; influenza serology
	R33010	Test; Legionnaires antibodies
	R33011	Test; RSV
	S33001	Test; microbiology; skin
	S33005	Test; varicella zoster serology
	S33006	Test; varicella zoster culture
	S33007	Test; nail M&C
	T33001	Test; microbiology; endoc/metabo
	U33002	Test; microbiology; urology

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Microbiology; other (continued)	W34004	Test; antenatal serology
	W33006	Test; microbiology; reproductive
	X33001	Test; microbiology; genital; female
	X33003	Culture; gonococcal; female
	Y33001	Test; microbiology; genital; male
	Y33003	Culture; gonococcal; male
	Y33004	Test; viral culture; genital; male
	Y33005	Test; urethral/penile swab
Monospot	A33002	Test; monospot
	A33014	Test; Paul Bunnell
	A33031	Test; Epstein Barr virus serol
	A33032	Test; Epstein Barr virus
Nose swab C&S	R33008	Test; nose swab M&C
Pertussis	R33007	Test; pertussis
Ross River fever	A33009	Test; Ross River Fever
Rubella	A33001	Test; rubella
Skin swab C&S	S33003	Test; skin swab M&C
Sputum C&S	R33005	Test; sputum M&C
Throat swab C&S	R33006	Test; throat swab M&C
Urine MC&S	U33001	Test; culture; urine
	U33004	Test; urine M&C
Vaginal swab and C&S	X33005	Test; vaginal swab M&C
Venereal disease	A33010	Test; venereal disease
	A33022	Test; syphilis serology
Simple test; other	B35001	Test; urine; blood
	D36003	Test; occult blood
	R32001	Test; Mantoux
	R32002	Test; tuberculin
Other NEC		
Blood test	A34001	Test; blood
Urine test	A35001	Test; urine
Urinalysis	A35002	Urinalysis
Faeces test	A36001	Test; faeces
Other pathology test NEC	A35006	Test; urine; FWT
	A38001	Test; other lab
	A38002	Pathology
	A38003	Test; genetic

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Other pathology test NEC (continued)	A38005	Test; disease screen
	B38001	Test; other lab; blood
	D34001	Test; blood; digestive
	D35001	Test; urine; digestive
	D36002	Test; faeces; digestive
	D38001	Test; other lab; digestive
	F34001	Test; blood; eye
	F38001	Test; other lab; eye
	H34001	Test; blood; ear
	H38001	Test; other lab; ear
	K34002	Test; blood; cardiovascular
	K38001	Test; other lab; cardiovascular
	L34003	Test; blood; musculoskeletal
	L38001	Test; other lab; musculoskeletal
	N34002	Test; blood; neurological
	N38001	Test; other lab; neurological
	P34001	Test; blood; psychological
	P35001	Test; urine; psychological
	P38001	Test; other lab; psychological
	R34001	Test; blood; respiratory
	R38001	Test; other lab; respiratory
	S34001	Test; blood; skin
	S38001	Test; other lab; skin
	T34002	Test; blood; endocr/metabolic
	T35001	Test; urine; endocrine/metabolic
	T38001	Test; other lab; endocr/metabol
	U34001	Test; blood; urology
	U35002	Test; urine; urology
	U38001	Test; other lab; urology
	W34001	Test; blood; reproductive
	W35001	Test; urine; reproductive
	W38001	Test; other lab; reproductive
	X34001	Test; blood; genital; female
	X35001	Test; urine; genital; female
	X38001	Test; other lab; genital; female
	Y34001	Test; blood; genital; male
	Y35001	Test; urine; genital; male

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Other pathology test NEC (continued)	Y38001	Test; other lab; genital; male
	Z38001	Test; other lab; social
IMAGING TEST ORDERS (MBS)		
Diagnostic radiology	A41001	Radiology; diagnostic
	A41002	X-ray; chest
	A41006	X-ray; abdomen
	A41007	Imaging other
	A41010	Radiology
	A41014	Test; imaging; contrast/special
	B41001	Radiology; diagnostic; blood
	D41001	GI series
	D41003	Radiology; diagnostic; digestive
	D41006	X-ray; oesophagus
	D41007	X-ray; biliary ducts
	D41008	X-ray; digestive tract
	D41009	X-ray; mouth
	D41012	X-ray; dental
	D41015	Barium enema
	D41016	Barium meal
	D41017	Barium swallow
	F41001	Radiology; diagnostic; eye
	F41002	X-ray; eye
	H41001	Radiology; diagnostic; ear
	H41002	X-ray; ear
	K41002	Radiology; diagnostic; cardiovas
	K41003	Cardiogram
	K41005	Angiography; coronary
	K41006	Angiography; femoral
	K41007	Angiography; cerebral
	K41011	Angiogram
	K41012	Angiogram; coronary
	K41013	Angiogram; cerebral
	K41014	Angiogram; femoral
	L41001	Arthrogram
	L41002	Scan; bone(s)
	L41003	X-ray; bone(s)
	L41004	Plain x-ray; bone(s)

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Diagnostic radiology (continued)	L41005	Radiology; diagnostic; musculo
	L41013	X-ray; elbow
	L41014	X-ray; hand
	L41015	X-ray; wrist
	L41016	X-ray; knee
	L41017	X-ray; hip
	L41018	X-ray; neck
	L41019	X-ray; pelvis
	L41020	X-ray; shoulder
	L41021	X-ray; lumbosacral
	L41022	X-ray; cervical
	L41023	X-ray; thoracic
	L41024	X-ray; spinal
	L41025	X-ray; joint(s)
	L41026	X-ray; foot/feet
	L41027	X-ray; ankle
	L41028	X-ray; leg
	L41029	X-ray; ribs
	L41030	X-ray; face
	L41032	X-ray; arm
	L41033	X-ray; spine; lumbar
	L41034	X-ray; spine; sacrum
	L41035	X-ray; spine; coccyx
	L41036	X-ray; finger(s)/thumb
	L41037	X-ray; toe(s)
	L41038	X-ray; heel
	L41039	X-ray; tibia/fibula
	L41040	X-ray; femur
	L41041	X-ray; radius/ulna
	L41042	X-ray; clavicle
	L41043	X-ray; humerus
	L41044	X-ray; jaw
	L41045	X-ray; temporomandibular joint
	L41060	X-ray; spine; cervicothoracic
	L41061	X-ray; spine; sacrococcygeal
	L41062	X-ray; spine; thoracolumbar
	L41063	X-ray; back

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Diagnostic radiology (continued)		
	L41064	X-ray; back lower
	L41065	X-ray; forearm
	L41066	X-ray; leg lower
	L41067	X-ray; metacarpal
	L41068	X-ray; metatarsal
	L43003	Test; bone density
	N41001	Radiology; diagnostic neurolog
	N41004	X-ray; skull
	P41001	Radiology; diagnostic; psychol
	R41001	Radiology; diagnostic; respirat
	R41002	X-ray; sinus
	R41003	X-ray; nose
	S41001	Radiology; diagnostic; skin
	T41001	Radiology; diagnostic; endo/meta
	T41003	X-ray; endo/metabolic
	U41001	Pyelogram; intravenous
	U41002	Pyelogram; retrograde
	U41005	Radiology; diagnostic; urology
	U41007	X-ray; urinary tract
	U41008	X-ray; kidney/ureter/bladder
	W41002	Radiology; diagnostic; reprod
	W41003	X-ray; uterus
	X41001	Mammography; female
	X41002	Mammography; request; female
	X41003	Thermography; breast
	X41005	Radiology; diagnostic; genital; female
	X41007	X-ray; breast; female
	Y41001	Radiology; diagnostic; genital; male
Ultrasound	A41012	Ultrasound
	A41015	Ultrasound; abdomen
	A41017	Ultrasound; chest
	A41021	Ultrasound; inguinal
	A41022	Ultrasound; abdomen; upper
	A41023	Ultrasound; abdomen; lower
	B41002	Ultrasound; spleen
	D41013	Ultrasound; gallbladder
	D41014	Ultrasound; liver

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Ultrasound (continued)	K41001	Echocardiography
	K41016	Ultrasound; cardiac
	K43003	Test; Doppler
	K43004	Test; Doppler carotid
	K43005	Scan; duplex
	L41046	Ultrasound; neck
	L41047	Ultrasound; pelvis
	L41048	Ultrasound; shoulder
	L41049	Ultrasound; spine
	L41050	Ultrasound; knee
	L41051	Ultrasound; elbow
	L41070	Ultrasound; wrist
	L41071	Ultrasound; ankle
	L41072	Ultrasound; groin
	L41073	Ultrasound; back
	L41074	Ultrasound; back lower
	L41075	Ultrasound; hand/finger(s)
	L41076	Ultrasound; foot/toe(s)
	L41078	Ultrasound; arm
	L41079	Ultrasound; leg
	N41005	Ultrasound; brain
	N41007	Ultrasound; head
	T41004	Ultrasound; thyroid
	U41009	Ultrasound; renal tract
	U41010	Ultrasound; kidney
	W41004	Ultrasound; obstetric
	X41009	Ultrasound; breast; female
	X41011	Ultrasound; uterus (not preg)
	Y41005	Ultrasound; prostate
	Y41006	Ultrasound; scrotum
	Y41008	Ultrasound; breast; male
	Computerised tomography	A41013
A41016		CT scan; abdomen
A41018		CT scan; chest
A41019		CT scan; abdomen; upper
A41020		CT scan; abdomen; lower
D41018		CT scan; liver

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Computerised tomography (continued)	K41017	CT scan; cardiac
	L41052	CT scan; neck
	L41053	CT scan; pelvis
	L41054	CT scan; spine
	L41055	CT scan; spine; cervical
	L41056	CT scan; spine; thoracic
	L41057	CT scan; spine; lumbar
	L41058	CT scan; spine; lumbosacral
	L41059	CT scan; spine; sacrum
	L41069	CT scan; spine; thoracolumbar
	L41077	CT scan; spine; cervicothoracic
	L41080	CT scan; leg
	N41006	CT scan; brain
	N41008	CT scan; head
	R41004	CT scan; sinus
	X41010	CT scan; breast; female
	Y41007	CT scan; breast; male
	Nuclear medicine	A41009
A41011		Isotope scan
K41015		Scan; thallium heart
R41005		Scan; VQ (lung)
Magnetic resonance imaging	A41008	MRI

Note: NOS—not otherwise specified; NEC—not elsewhere classified; A & E—accident and emergency; MBS—Medicare Benefits Schedule; ‘-code’—signifies that the concept includes all of the specified code across all chapters of ICPC-2 (excluding the Z social chapter). Codes listed in this appendix are only those that are currently active within ICPC-2 PLUS.

Appendix 4: Chronic code groups from ICPC-2 and ICPC-2 PLUS

Table A4.1: Chronic code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC/ICPC-2 PLUS label
CHRONIC PROBLEMS MANAGED			
Acne (chronic)		S96007	Acne
		S96003	Acne; conglobulate
		S96002	Acne; vulgaris
Anaemia (chronic)	B81		Anaemia, vitamin B12/folate deficiency
	B82		Anaemia, other/unspecified
Arthritis		L83010	Arthritis; spine cervical
		L84003	Arthritis; spine
		L84023	Arthritis; spine thoracic
		L84024	Arthritis; spine lumbar
		L84025	Arthritis; lumbosacral
		L84026	Arthritis; sacroiliac
		L89004	Arthritis; hip
		L90004	Arthritis; knee
		L91007	Arthritis; degenerative
		L91009	Arthritis
		L91010	Arthritis; acute
		L91011	Arthritis; allergic
		L91012	Polyarthritis
		L91013	Arthritis; hands/fingers
		L91014	Arthritis; wrist
Diabetes (non-gestational)		L92006	Arthritis; shoulder
		S91002	Arthritis; psoriatic
	T89		Diabetes, insulin dependent
	T90		Diabetes, non-insulin dependent
Hypertension (non-gestational)	K86		Hypertension, uncomplicated
	K87		Hypertension, complicated
Sprain/strain		L83023	Sprain; neck
		L83024	Strain; neck
		L83025	Whiplash injury; neck old
		L84020	Sprain; back
		L84021	Strain; back

Note: The code groups listed in Appendix 4 are those which differ from other code groups used in the report (see Appendix 3), limiting analysis to only chronic conditions.

Appendix 5: Summary of annual results 2000-01 to 2004-05

Table A5.1: GP characteristics, summary of annual results BEACH 2000-01 to 2004-05

GP characteristic	2000-01		2001-02		2002-03		2003-04		2004-05	
	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =999)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =983)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,008)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,000)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =953)
Sex (missing)	(0)	—	(0)	—	(0)	—	(0)	—	(0)	—
Male	683	68.4	631	64.2	653	64.8	673	67.3	647	67.9
Female	316	31.6	352	35.8	355	35.2	327	32.7	306	32.1
Age (missing)	(9)	—	(1)	—	(0)	—	(1)	—	(1)	—
<35 years	67	6.7	70	7.1	74	7.3	58	5.8	86	8.9
35-44 years	284	28.4	263	26.8	268	26.6	249	24.9	243	25.5
45-54 years	342	34.2	359	36.5	355	35.2	365	36.5	303	31.8
55+ years	297	29.7	290	29.5	311	30.9	327	32.7	320	33.6
Years in general practice (missing)	(6)	—	(4)	—	(6)	—	(9)	—	(5)	—
<2 years	5	0.5	3	0.3	6	0.6	13	1.3	4	0.4
2-5 years	64	6.4	71	7.2	75	7.5	53	5.3	98	10.3
6-10 years	137	13.7	132	13.4	135	13.5	106	10.7	119	12.6
11-19 years	299	29.9	279	28.4	281	28.0	278	28.1	241	25.4
20+ years	488	48.8	494	50.3	505	50.4	541	54.6	486	51.3
Sessions per week (missing)	(16)	—	(15)	—	(8)	—	(7)	—	(8)	—
<6 per week	159	15.9	157	16.0	187	18.7	171	17.2	136	14.4
6-10 per week	662	66.3	666	67.8	679	67.9	687	68.2	701	71.2
11+ per week	162	16.2	145	14.8	134	13.4	135	13.6	108	11.4

(continued)

Table A5.1 (continued): GP characteristics, summary of annual results BEACH 2000-01 to 2004-05

GP characteristic	2000-01		2001-02		2002-03		2003-04		2004-05	
	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =999)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =983)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,008)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,000)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =953)
Size of practice (missing)	(28)	—	(4)	—	(8)	—	(10)	—	(6)	—
Solo	187	19.3	150	15.3	137	13.7	105	10.6	116	12.2
2-4 GPs	375	38.6	390	39.7	384	38.4	374	37.8	345	36.4
5+ GPs	409	42.1	439	44.7	479	47.9	511	51.6	486	51.3
Place of graduation (missing)	(0)	—	(0)	—	(0)	—	(1)	—	(1)	—
Australia	726	72.7	748	76.1	726	72.6	735	73.5	665	69.8
United Kingdom	82	8.2	75	7.6	92	9.1	72	7.2	72	7.6
Asia	47	4.7	85	8.6	100	9.9	95	9.5	104	10.9
Europe	19	1.9	18	1.8	16	1.6	23	2.3	36	3.8
Africa	15	1.5	36	3.7	43	4.3	54	5.4	51	5.4
New Zealand	15	1.5	5	0.5	22	2.2	10	1.0	12	1.3
Other	95	9.5	16	1.6	9	0.9	10	1.0	12	1.3
Practice location (missing)	(0)	—	(1)	—	(0)	—	(2)	—	(1)	—
Capital	680	68.1	681	69.3	652	64.7	623	62.4	618	64.9
Other metropolitan	69	6.9	80	8.1	86	8.5	64	6.4	64	6.7
Large rural	55	5.6	58	5.9	51	5.1	70	7.0	51	5.4
Small rural	56	5.6	48	4.9	78	7.7	70	7.0	66	6.9
Other rural	122	12.2	103	10.5	121	12.0	142	14.2	124	13.0
Remote central	10	1.0	4	0.5	6	0.6	9	0.9	12	1.3
Other remote, offshore	7	0.7	8	0.8	14	1.4	20	2.0	17	1.8

(continued)

Table A5.1 (continued): GP characteristics, summary of annual results BEACH 2000-01 to 2004-05

GP characteristic	2000-01		2001-02		2002-03		2003-04		2004-05	
	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =999)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =983)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,008)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,000)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =953)
Consultations in Languages other than English (missing)*	(0)	—	—	—	—	—	(6)	—	(1)	—
<25%	NAv	NAv	NAv	NAv	NAv	NAv	177	17.8	207	21.7
25-50%	NAv	NAv	NAv	NAv	NAv	NAv	29	2.9	23	2.4
>50%	135	13.5	NAv	NAv	NAv	NAv	24	2.4	32	3.4
Currently in a general practice vocational training program	25	2.5	25	2.5	28	2.9	43	4.4	33	3.5
Completed training program	316	31.6	375	38.1	377	39.5	NAv	NAv	NAv	NAv
Fellow of RACGP	314	31.4	345	35.1	355	35.5	332	33.5	399	42.3
Own or cooperative after-hours arrangements	646	64.7	550	56.0	551	55.2	593	59.6	492	52.1
Computer use at practice	873	87.4	883	89.7	920	91.3	950	95.0	880	93.7

(a) Missing data removed.

* Data for all three groupings only available from 2003-04.

Note: NAv—not available; RACGP—Royal Australian College of General Practitioners.

Table A5.2: Summary of morbidity and management, summary of annual results BEACH 2000-01 to 2004-05

Variable	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=98,877)	Rate per 100 encounters (95% CI) (n=94,386)
Reasons for encounter	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (148.4–152.0)	149.6 (147.8–151.5)
Problems managed	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	146.3 (144.4–148.2)	145.5 (143.6–147.4)
New problems	47.4 (45.7–49.0)	55.1 (53.8–56.5)	57.0 (55.6–58.3)	55.9 (54.5–57.3)	55.2 (53.8–56.5)
Chronic problems	47.4 (45.8–48.9)	48.4 (46.9–49.9)	48.2 (46.5–49.8)	50.8 (49.0–52.5)	50.8 (49.1–52.5)
Work-related	3.3 (3.1–3.6)	3.0 (2.7–3.2)	NAv	NAv	3.1 (2.8–3.5)
Medications	108.2 (105.7–110.6)	104.5 (102.2–106.9)	103.8 (101.4–106.2)	104.4 (102.1–106.7)	101.5 (99.3–103.8)
Prescribed	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	86.0 (83.6–88.5)	83.4 (81.2–85.5)
GP-supplied	6.9 (5.7–8.1)	7.6 (6.3–9.0)	9.3 (7.6–11.0)	8.6 (7.4–9.8)	8.1 (7.3–8.9)
Advised OTC	9.0 (8.1–9.8)	8.9 (8.1–9.6)	10.2 (9.2–11.1)	9.8 (9.0–10.6)	10.1 (9.1–11.0)
Non-pharmacological treatments	49.4 (47.1–51.7)	51.9 (49.6–54.2)	51.8 (49.3–54.3)	51.4 (48.9–53.8)	54.7 (52.1–57.3)
Clinical	37.2 (35.1–39.3)	38.1 (36.1–40.1)	37.2 (35.0–39.4)	36.6 (34.5–38.8)	39.2 (37.1–41.4)
Procedural	12.2 (11.6–12.8)	13.8 (13.1–14.5)	14.6 (13.9–15.3)	14.7 (14.0–15.5)	15.5 (14.6–16.4)
Referrals	10.4 (10.0–10.8)	10.5 (10.1–10.9)	11.1 (10.7–11.6)	11.6 (11.1–12.1)	11.5 (11.1–12.0)
Specialist	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.7 (7.3–8.0)	7.9 (7.5–8.2)	7.7 (7.4–8.0)
Allied health services	2.3 (2.1–2.5)	2.6 (2.3–2.9)	2.5 (2.3–2.8)	2.6 (2.4–2.9)	2.7 (2.5–2.9)
Hospital	0.5 (0.3–0.7)	0.4 (0.3–0.6)	0.6 (0.3–0.8)	0.6 (0.3–0.8)	0.5 (0.3–0.7)
Emergency department	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.2 (0.0–0.5)	0.2 (0.0–0.4)
Other referrals	0.1 (0.0–0.6)	0.3 (0.0–0.6)	0.3 (0.0–0.5)	0.3 (0.0–0.6)	0.3 (0.1–0.6)
Pathology ⁺	29.7 (28.4–30.9)	31.0 (29.7–32.4)	32.9 (31.5–34.4)	35.2 (33.7–36.7)	36.7 (35.2–38.2)
Imaging	7.7 (7.3–8.0)	7.9 (7.6–8.2)	8.6 (8.2–9.0)	8.2 (7.8–8.6)	8.3 (8.0–8.6)
Other investigations	0.6 (0.4–0.8)	0.9 (0.8–1.0)	1.0 (0.8–1.2)	1.0 (0.9–1.2)	1.1 (0.9–1.3)

+ From the third year of BEACH (2000-01) the data collection and coding system for pathology changed.

Note: CI—confidence interval; NAv—not available; OTC—over-the-counter.

Table A5.3: Type of encounter, summary of annual results BEACH 2000-01 to 2004-05

Variable	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters (95% CI) ^(a) (n=99,307)	Rate per 100 encounters (95% CI) ^(a) (n=96,973)	Rate per 100 encounters (95% CI) ^(a) (n=100,987)	Rate per 100 encounters (95% CI) ^(a) (n=98,877)	Rate per 100 encounters (95% CI) ^(a) (n=94,386)
Direct encounters	98.1 (97.8–98.4)	97.7 (97.4–98.0)	98.4 (98.2–98.6)	97.0 (96.6–97.3)	97.4 (97.1–97.7)
No charge	0.6 (0.0–1.5)	0.6 (0.2–1.1)	0.5 (0.2–0.8)	0.5 (0.3–0.7)	0.5 (0.2–0.9)
Medicare-claimable ^(b)	94.6 (94.2–95.0)	93.9 (93.5–94.4)	95.0 (94.6–95.3)	93.8 (93.3–94.2)	93.7 (93.3–94.2)
Short surgery consultations	1.5 (0.5–2.5)	1.0 (0.5–1.6)	1.1 (0.6–1.7)	1.1 (0.4–1.7)	1.0 (0.3–1.6)
Standard surgery consultations	79.4 (78.4–80.3)	79.0 (78.0–79.9)	78.7 (77.6–79.7)	77.3 (76.2–78.4)	77.2 (76.0–78.2)
Long surgery consultations	8.4 (7.7–9.0)	8.1 (7.5–8.7)	9.1 (8.5–9.7)	9.2 (8.5–9.8)	9.9 (9.2–10.6)
Prolonged surgery consultations	0.6 (0.0–1.2)	0.6 (0.0–1.2)	0.7 (0.0–1.5)	0.7 (0.0–1.4)	0.7 (0.1–1.3)
Home visits	1.5 (0.5–2.4)	1.5 (0.8–2.2)	1.3 (0.4–2.1)	1.3 (0.1–2.5)	0.9 (0.2–1.6)
Hospital	0.2 (0.0–1.7)	0.2 (0.0–1.4)	0.4 (0.0–2.7)	0.3 (0.0–1.7)	0.2 (0.0–2.0)
Residential aged care facility	0.7 (0.0–2.1)	0.9 (0.0–2.4)	1.2 (0.0–2.9)	1.1 (0.0–2.3)	1.1 (0.0–3.2)
Case conference	N/A	0.0 [‡] (0.0–2.3)	0.0 [‡] (0.0–1.4)	0.0 [‡] (0.0–1.2)	0.0 [‡] (0.0–1.4)
Care plans	N/A	0.1 (0.0–1.7)	0.1 (0.0–1.0)	0.1 (0.0–1.3)	0.2 (0.0–0.9)
Health assessments	N/A	0.1 (0.0–0.7)	0.1 (0.0–0.6)	0.1 (0.0–0.7)	0.2 (0.0–0.7)
Other items	2.4 (1.3–3.5)	2.4 (1.4–3.5)	2.3 (1.1–3.5)	2.6 (1.3–4.0)	2.4 (0.6–4.2)
Workers' compensation	2.1 (1.8–2.4)	2.0 (1.8–2.3)	1.9 (1.6–2.2)	2.0 (1.8–2.3)	2.5 (2.1–2.8)
Other paid (hospital, state, etc.)	0.8 (0.0–1.6)	1.1 (0.2–2.0)	1.0 (0.2–1.8)	0.6 (0.0–1.4)	0.7 (0.1–1.3)
Indirect encounters	1.9 (1.2–2.6)	2.3 (1.8–2.8)	1.6 (1.2–2.0)	3.1 (2.5–3.6)	2.6 (2.1–3.1)

(a) Missing data removed.

(b) Includes encounters that were recorded as claimable through the Australian Department of Veterans' Affairs.

‡ Rates are reported to one decimal place. This indicates that the rate is <0.05 per 100 encounters.

Note: CI—confidence interval; N/A—not applicable.

Table A5.4: Characteristics of the patients at encounters, summary of annual results BEACH 2000-01 to 2004-05

Patient variable	2000-01	2001-02	2002-03	2003-04	2004-05
	Per cent of encounters (95% CI) (n=99,307)	Per cent of encounters (95% CI) (n=96,973)	Per cent of encounters (95% CI) (n=100,987)	Per cent of encounters (95% CI) (n=98,877)	Per cent of encounters (95% CI) (n=94,386)
Sex					
Male	42.9 (42.2-43.6)	42.6 (41.9-43.3)	42.2 (41.4-42.9)	42.6 (41.8-43.3)	43.5 (42.7-44.3)
Female	57.1 (56.4-57.8)	57.4 (56.7-58.1)	57.8 (57.0-58.6)	57.4 (56.7-58.2)	56.5 (55.7-57.3)
Age group					
<1 year	2.1 (1.9-2.4)	2.0 (1.8-2.1)	1.9 (1.8-2.1)	1.8 (1.6-2.0)	1.9 (1.7-2.1)
1-4 years	5.4 (5.1-5.7)	4.9 (4.6-5.2)	5.0 (4.7-5.3)	4.6 (4.3-4.8)	4.3 (4.0-4.7)
5-14 years	6.8 (6.4-7.2)	6.4 (6.1-6.7)	6.6 (6.3-6.9)	5.9 (5.6-6.3)	5.8 (5.5-6.1)
15-24 years	10.3 (9.8-10.7)	9.5 (9.1-10.0)	10.1 (9.7-10.4)	9.6 (9.2-10.1)	9.0 (8.6-9.4)
25-44 years	26.3 (25.6-27.0)	25.8 (25.1-26.5)	25.7 (24.9-26.4)	24.1 (23.4-24.8)	24.4 (23.7-25.1)
45-64 years	26.1 (25.5-26.7)	26.3 (25.7-26.8)	26.5 (25.9-27.0)	27.2 (26.7-27.7)	28.0 (27.4-28.6)
65-74 years	11.7 (11.2-12.2)	12.3 (11.8-12.8)	11.6 (11.1-12.0)	12.4 (11.9-12.9)	12.6 (12.1-13.2)
75+ years	11.3 (10.7-12.0)	12.8 (12.0-13.5)	12.7 (11.9-13.4)	14.4 (13.6-15.2)	13.9 (13.1-14.7)
Other characteristics					
New patient to practice	8.0 (7.1-8.8)	9.2 (8.5-9.9)	9.9 (9.0-10.8)	9.3 (8.5-10.0)	9.1 (8.3-9.9)
Commonwealth concession card	36.7 (35.1-38.3)	41.9 (40.4-43.3)	40.4 (38.8-41.9)	42.5 (41.0-44.0)	43.2 (41.8-44.7)
Repatriation health card ^(a)	3.1 (2.8-3.4)	3.3 (3.0-3.6)	3.3 (3.0-3.6)	3.5 (3.2-3.8)	3.2 (2.8-3.5)
Non-English-speaking background	8.0 (4.8-11.1)	9.3 (5.9-12.7)	10.6 (7.8-13.4)	9.7 (5.8-13.6)	10.8 (7.2-14.4)
Aboriginal person	0.7 (0.0-1.5)	0.9 (0.0-2.0)	0.8 (0.0-1.7)	1.4 (0.0-2.9)	1.1 (0.0-3.0)
Torres Strait Islander	0.1 (0.0-0.7)	0.1 (0.0-0.5)	0.1 (0.0-0.9)	0.2 (0.0-1.0)	0.2 (0.0-1.8)

(a) The 1999-00 results reported here are for gold card holders only.

Note: CI—confidence interval.

Table A5.5: Rate of patient reasons for encounter by ICPC-2 chapter, summary of annual results BEACH 2000-01 to 2004-05

Reasons for encounter	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
General & unspecified	28.3 (27.5–29.1)	30.9 (29.9–31.8)	34.6 (33.6–35.6)	36.2 (35.2–37.2)	36.5 (35.5–37.6)
Respiratory	24.6 (23.7–25.4)	23.4(22.6–24.2)	23.0 (22.0–24.0)	21.4 (20.6–22.2)	20.6 (19.8–21.4)
Musculoskeletal	17.7 (17.1–18.2)	16.7 (16.1–17.3)	17.7 (17.2–18.3)	16.3 (15.7–16.9)	16.7 (16.0–17.3)
Skin	15.5 (15.0–16.0)	14.4 (13.9–14.9)	14.7 (14.3–15.2)	15.1 (14.5–15.7)	15.6 (15.0–16.2)
Circulatory	11.7 (11.1–12.2)	11.4 (10.8–11.9)	10.6 (10.0–11.1)	10.7 (10.1–11.2)	10.5 (10.0–11.0)
Digestive	11.1 (10.7–11.5)	10.6 (10.2–11.0)	10.4 (10.0–10.8)	10.7 (10.3–11.2)	9.9 (9.5–10.3)
Psychological	8.1 (7.7–8.6)	7.8 (7.3–8.3)	7.3 (6.9–7.8)	7.3 (6.9–7.7)	7.6 (7.2–8.0)
Endocrine & metabolic	6.2 (5.9–6.5)	6.4 (6.1–6.7)	6.0 (5.7–6.3)	6.2 (5.8–6.5)	6.2 (5.8–6.5)
Female genital system	5.5 (5.1–5.9)	5.5 (5.1–5.9)	6.1 (5.7–6.6)	5.1 (4.8–5.5)	5.0 (4.6–5.4)
Neurological	5.8 (5.5–6.0)	5.4 (5.2–5.6)	5.7 (5.5–6.0)	5.3 (5.1–5.6)	5.1 (4.9–5.4)
Ear	4.2 (4.0–4.3)	4.2 (4.0–4.4)	4.0 (3.8–4.1)	3.7 (3.6–3.9)	3.9 (3.7–4.1)
Pregnancy & family planning	3.5 (3.2–3.8)	3.5 (3.2–3.8)	3.6 (3.3–3.9)	3.7 (3.4–4.0)	3.4 (3.1–3.7)
Eye	2.7 (2.5–2.8)	2.5 (2.4–2.7)	2.7 (2.6–2.9)	2.7 (2.6–2.9)	2.7 (2.6–2.9)
Urology	2.4 (2.3–2.6)	2.5 (2.4–2.7)	2.5 (2.3–2.6)	2.5 (2.4–2.7)	2.5 (2.4–2.7)
Blood	2.0 (1.8–2.2)	1.1 (0.9–1.2)	1.0 (0.8–1.2)	1.3 (1.1–1.4)	1.2 (1.0–1.5)
Male genital system	1.1 (1.0–1.3)	1.0 (0.9–1.1)	1.0 (0.9–1.2)	1.1 (0.9–1.2)	1.2 (1.1–1.4)
Social problems	0.9 (0.7–1.1)	1.0 (0.8–1.1)	1.0 (0.8–1.2)	0.9 (0.8–1.1)	1.0 (0.8–1.1)
Total RFEs	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (148.4–152.0)	149.6 (147.8–151.5)

(a) Figures do not total 100 as more than one RFE can be recorded for each encounter.

Note: CI—confidence interval; RFE—reason for encounter.

Table A5.6: Rate of RFEs by ICPC-2 component, summary of annual results BEACH 2000-01 to 2004-05

	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
ICPC-2 component					
Symptoms & complaints	76.6 (74.6-78.6)	74.1 (72.3-75.9)	74.0 (72.0-76.1)	71.7 (69.8-73.5)	71.3 (69.4-73.2)
Diagnosis, diseases	29.0 (27.6-30.5)	27.3 (25.9-28.7)	26.0 (24.6-27.4)	25.1 (23.9-26.4)	24.5 (23.3-25.7)
Diagnostic & preventive procedures	22.3 (21.4-23.2)	22.7 (21.7-23.6)	23.8 (22.8-24.7)	24.0 (23.1-25.0)	23.4 (22.5-24.3)
Medications, treatments & therapeutics	11.2 (10.6-11.8)	11.9 (11.3-12.4)	13.0 (12.4-13.6)	14.4 (13.7-15.1)	14.5 (13.8-15.3)
Referral & other RFE	6.5 (6.0-7.0)	7.2 (6.7-7.7)	7.0 (6.6-7.5)	7.2 (6.8-7.6)	7.4 (6.9-7.9)
Results	4.2 (3.9-4.6)	4.7 (4.4-5.1)	5.4 (5.0-5.7)	6.0 (5.6-6.4)	6.8 (6.4-7.2)
Administrative	1.1 (0.9-1.3)	1.3 (1.1-1.5)	1.6 (1.4-1.8)	1.8 (1.6-1.9)	1.7 (1.5-1.8)
Total RFEs	151.0 (149.2-152.8)	149.2 (147.4-150.9)	150.9 (149.0-152.7)	150.2 (148.4-152.0)	149.6 (147.8-151.5)

(a) Figures do not total 100 as more than one RFE can be recorded for each encounter.

Note: CI—confidence interval; RFE—reason for encounter.

Table A5.7: Distribution of problems managed, summary of annual results BEACH 2000-01 to 2004-05

Problem managed	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Respiratory	22.5 (21.9–23.2)	21.4 (20.7–22.0)	20.6 (20.0–21.3)	20.1 (19.5–20.7)	19.2 (18.6–19.9)
Musculoskeletal	17.4 (16.9–18.0)	17.5 (17.0–18.0)	17.1 (16.5–17.6)	17.1 (16.6–17.6)	17.7 (17.1–18.3)
Skin	16.7 (16.2–17.3)	16.1 (15.6–16.6)	16.5 (16.0–17.0)	16.9 (16.2–17.6)	17.2 (16.6–17.9)
Circulatory	16.0 (15.3–16.7)	16.1 (15.5–16.8)	16.0 (15.3–16.7)	16.8 (16.1–17.5)	16.2 (15.5–16.9)
General & unspecified	14.2 (13.7–14.7)	14.7 (14.0–15.5)	15.8 (15.2–16.3)	15.0 (14.5–15.5)	15.1 (14.5–15.7)
Endocrine & metabolic	9.8 (9.3–10.2)	10.4 (10.0–10.9)	10.6 (10.2–11.0)	11.3 (10.8–11.8)	11.8 (11.2–12.3)
Psychological	10.8 (10.2–11.3)	10.6 (10.1–11.2)	10.3 (9.8–10.8)	10.8 (10.3–11.4)	11.4 (10.8–12.0)
Digestive	9.9 (9.6–10.2)	9.9 (9.6–10.2)	10.1 (9.8–10.4)	10.5 (10.2–10.8)	9.9 (9.6–10.2)
Female genital system	6.1 (5.7–6.4)	6.1 (5.8–6.5)	6.7 (6.2–7.1)	5.9 (5.5–6.3)	5.7 (5.3–6.1)
Ear	4.4 (4.2–4.6)	4.2 (4.0–4.4)	4.0 (3.8–4.2)	4.0 (3.8–4.1)	4.1 (3.9–4.2)
Pregnancy & family planning	3.9 (3.6–4.2)	4.0 (3.7–4.3)	4.2 (3.8–4.5)	4.2 (3.9–4.5)	3.8 (3.5–4.1)
Neurological	3.8 (3.6–3.9)	3.7 (3.5–3.9)	4.2 (4.0–4.4)	3.9 (3.8–4.1)	3.6 (3.5–3.8)
Urology	2.7 (2.5–2.8)	2.8 (2.7–3.0)	2.8 (2.7–3.0)	3.0 (2.9–3.2)	3.0 (2.9–3.2)
Eye	2.6 (2.5–2.7)	2.5 (2.4–2.6)	2.6 (2.5–2.7)	2.7 (2.6–2.9)	2.7 (2.5–2.9)
Male genital system	1.5 (1.3–1.6)	1.3 (1.1–1.4)	1.4 (1.3–1.6)	1.6 (1.4–1.7)	1.8 (1.6–1.9)
Blood	1.7 (1.5–1.8)	1.3 (1.2–1.4)	1.4 (1.2–1.5)	1.7 (1.5–1.8)	1.6 (1.4–1.8)
Social problems	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.8 (1.6–1.0)	0.8 (0.6–1.0)
Total problems	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	146.3 (144.4–148.2)	145.5 (143.6–147.7)

(a) Figures do not total 100 as more than one problem can be managed at each encounter.

Note: CI—confidence interval.

Table A5.8: Most frequently managed problems, summary of annual results BEACH 2000-01 to 2004-05

Problem managed	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Hypertension*	8.6 (8.2–9.1)	9.0 (8.6–9.5)	8.9 (8.4–9.3)	9.2 (8.7–9.7)	8.9 (8.4–9.4)
Upper respiratory tract infection	6.9 (6.5–7.4)	6.2 (5.8–6.6)	6.4 (5.9–6.8)	5.5 (5.1–5.9)	5.6 (5.1–6.0)
Immunisation/vaccination—all*	4.6 (4.2–5.0)	4.7 (4.2–5.1)	4.6 (4.2–5.1)	4.7 (4.2–5.2)	4.6 (4.1–5.2)
Depression*	3.7 (3.4–3.9)	3.4 (3.2–3.6)	3.5 (3.3–3.8)	3.7 (3.4–3.8)	3.7 (3.5–3.9)
Lipid disorder	2.9 (2.7–3.1)	2.9 (2.7–3.1)	3.0 (2.8–3.2)	3.3 (3.1–3.5)	3.3 (3.1–3.6)
Diabetes*	2.8 (2.6–3.0)	3.1 (2.9–3.3)	2.9 (2.7–3.1)	3.1 (2.9–3.4)	3.2 (3.0–3.4)
Back complaint*	2.6 (2.4–2.8)	2.6 (2.4–2.8)	2.6 (2.3–2.8)	2.7 (2.5–2.9)	2.8 (2.6–3.0)
Osteoarthritis*	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.6 (2.4–2.8)	2.8 (2.6–3.0)	2.8 (2.6–3.0)
Acute bronchitis/bronchiolitis	2.7 (2.5–3.0)	2.7 (2.5–3.0)	2.6 (2.3–2.8)	2.4 (2.2–2.6)	2.4 (2.1–2.7)
Asthma	2.8 (2.7–3.0)	2.8 (2.6–3.0)	2.7 (2.5–2.9)	2.6 (2.4–2.7)	2.3 (2.2–2.5)
Total problems	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	146.3 (144.4–148.2)	145.5 (143.6–147.4)

(a) Figures do not total 100 as more than one problem can be managed at each encounter. Also only the most frequent problems are included.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 3, <www.aihw.gov.au/publications/index.cfm>).

Note: CI—confidence interval.

Table A5.9: Distribution of medications prescribed by CAPS group and subgroup, summary of annual results BEACH 2000-01 to 2004-05

Group and subgroup	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Antibiotics	15.9 (15.3–16.5)	14.4 (13.9–14.9)	13.8 (13.2–14.4)	14.2 (13.6–14.7)	14.6 (14.1–15.2)
Broad-spectrum penicillin	4.9 (4.6–5.2)	4.5 (4.2–4.8)	4.7 (4.4–5.1)	5.0 (4.6–5.3)	5.2 (4.9–5.6)
Cephalosporins	4.0 (3.6–4.3)	3.2 (3.0–3.5)	3.0 (2.8–3.2)	2.9 (2.7–3.1)	3.3 (3.0–3.6)
Other antibiotics	3.3 (3.1–3.6)	3.0 (2.8–3.2)	2.8 (2.6–3.0)	2.8 (2.6–3.0)	2.8 (2.6–3.0)
Penicillins	1.3 (1.1–1.4)	1.5 (1.2–1.7)	1.2 (1.0–1.4)	1.3 (1.2–1.5)	1.1 (0.9–1.2)
Tetracycline	1.1 (1.0–1.3)	1.0 (0.8–1.2)	0.9 (0.7–1.0)	0.9 (0.7–1.0)	0.9 (0.8–1.1)
Cardiovascular	13.6 (12.8–14.4)	13.9 (13.2–14.7)	13.1 (12.3–13.9)	14.4 (13.6–15.2)	14.1 (13.3–14.9)
Anti-hypertensives	7.3 (6.9–7.7)	7.5 (7.1–8.0)	7.3 (6.8–7.8)	8.1 (7.6–8.5)	7.9 (7.4–8.4)
Other cardiovascular drugs	2.6 (2.4–2.8)	2.7 (2.5–2.9)	2.6 (2.4–2.8)	2.9 (2.7–3.1)	3.1 (2.9–3.3)
Beta-blockers	1.6 (1.4–1.8)	1.7 (1.5–1.9)	1.5 (1.3–1.7)	1.7 (1.5–1.9)	1.6 (1.4–1.7)
Anti-angina	1.1 (0.9–1.3)	1.1 (0.9–1.3)	0.8 (0.6–1.1)	1.0 (0.8–1.2)	0.7 (0.5–0.9)
Central nervous system	11.1 (10.5–11.7)	10.7 (10.1–11.2)	10.5 (10.0–11.1)	10.5 (9.9–11.1)	10.2 (9.7–10.7)
Simple analgesics	4.8 (4.3–5.2)	3.8 (3.4–4.1)	3.9 (3.4–4.3)	3.6 (3.1–4.0)	3.4 (3.0–3.7)
Compound analgesics	2.7 (2.5–2.9)	2.7 (2.5–2.9)	2.4 (2.2–2.6)	2.5 (2.3–2.7)	2.4 (2.2–2.6)
Anti-emetic/anti-nausea	1.5 (1.3–1.6)	1.4 (1.2–1.5)	1.3 (1.2–1.5)	1.4 (1.3–1.5)	1.1 (1.0–1.3)
Narcotic analgesics	1.4 (1.0–1.8)	2.0 (1.6–2.4)	2.2 (1.9–2.6)	2.3 (2.1–2.6)	2.5 (2.2–2.9)
Psychological	7.5 (7.1–7.9)	7.4 (7.0–7.8)	7.0 (6.6–7.4)	7.6 (7.2–8.0)	7.4 (7.0–7.8)
Anti-depressants	3.1 (2.8–3.3)	2.9 (2.7–3.1)	2.9 (2.7–3.1)	3.2 (3.0–3.4)	3.1 (2.9–3.2)
Anti-anxiety	2.0 (1.8–2.2)	1.9 (1.7–2.2)	1.9 (1.7–2.1)	2.0 (1.8–2.2)	2.0 (1.7–2.2)
Sedative hypnotics	1.9 (1.7–2.1)	1.9 (1.7–2.2)	1.7 (1.6–1.9)	1.8 (1.7–2.0)	1.9 (1.7–2.2)

(continued)

Table A5.9 (continued): Distribution of medications prescribed by CAPS group and subgroup, summary of annual results BEACH 2000-01 to 2004-05

Group and subgroup	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Hormones	5.9 (5.6–6.2)	6.1 (5.8–6.4)	5.4 (5.1–5.7)	5.7 (5.3–6.0)	5.3 (5.0–5.6)
Sex/anabolic hormones	2.1 (1.9–2.2)	2.0 (1.8–2.1)	1.8 (1.6–1.9)	1.5 (1.3–1.7)	1.3 (1.1–1.4)
Hypoglycaemics	2.0 (1.7–2.3)	2.2 (1.9–2.5)	1.9 (1.6–2.2)	2.2 (1.9–2.4)	2.1 (1.8–2.3)
Corticosteroids	1.2 (1.1–1.4)	1.3 (1.2–1.5)	1.1 (0.9–1.2)	1.3 (1.1–1.4)	1.2 (1.1–1.4)
Other hormones	0.6 (0.5–0.7)	0.6 (0.5–0.8)	0.6 (0.5–0.8)	0.7 (0.6–0.9)	0.7 (0.5–0.9)
Musculoskeletal	6.8 (6.4–7.1)	6.1 (5.8–6.4)	5.7 (5.4–6.0)	5.6 (5.3–5.8)	5.3 (5.0–5.5)
NSAID/anti-rheumatoid	5.7 (5.4–6.0)	5.3 (5.0–5.5)	4.8 (4.5–5.0)	4.7 (4.5–4.9)	4.4 (4.2–4.7)
Respiratory	6.3 (5.9–6.7)	5.8 (5.3–6.2)	5.3 (4.9–5.7)	4.6 (4.3–4.9)	4.3 (4.0–4.6)
Bronchodilators	3.2 (2.9–3.4)	2.9 (2.6–3.1)	2.5 (2.2–2.7)	2.2 (2.0–2.4)	2.1 (1.9–2.2)
Asthma preventives	2.2 (2.0–2.4)	2.2 (2.0–2.4)	2.0 (1.9–2.2)	1.8 (1.7–2.0)	1.7 (1.5–1.8)
Skin	4.8 (4.5–5.2)	4.1 (3.9–4.4)	3.9 (3.7–4.2)	3.9 (3.7–4.1)	4.0 (3.8–4.3)
Topical steroids	3.1 (2.8–3.3)	2.8 (2.6–3.0)	2.6 (2.5–2.8)	2.6 (2.4–2.8)	2.8 (2.6–2.9)
Anti-infection, skin	0.9 (0.7–1.1)	0.7 (0.5–0.8)	0.7 (0.5–0.8)	0.7 (0.6–0.8)	0.7 (0.5–0.8)
Other skin	0.9 (0.6–1.1)	0.6 (0.4–0.8)	0.6 (0.4–0.8)	0.6 (0.4–0.8)	0.6 (0.4–0.7)
Digestive	4.1 (3.8–4.3)	3.8 (3.6–4.1)	3.9 (3.6–4.1)	4.2 (4.0–4.8)	3.8 (3.6–4.0)
Anti-ulcerants	2.2 (2.0–2.3)	2.4 (2.2–2.5)	2.4 (2.2–2.6)	2.7 (2.6–2.9)	2.6 (2.4–2.8)
Anti-diarrhoeals	0.5 (0.3–0.8)	0.5 (0.3–0.7)	0.5 (0.3–0.7)	0.5 (0.3–0.6)	0.4 (0.2–0.6)
Allergy, immune system	4.6 (4.2–5.0)	4.5 (4.1–4.8)	4.8 (4.3–5.3)	3.8 (3.4–4.2)	3.4 (2.9–3.9)
Immunisation	3.9 (3.4–4.3)	3.9 (3.5–4.3)	4.2 (3.7–4.7)	3.3 (2.9–3.7)	3.0 (2.4–3.5)

(continued)

Table A5.9 (continued): Distribution of medications prescribed by CAPS group and subgroup, summary of annual results BEACH 2000-01 to 2004-05

Group and subgroup	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Blood	1.8 (1.7–2.0)	1.8 (1.7–2.0)	1.7 (1.6–1.9)	2.1 (1.9–2.3)	2.0 (1.8–2.2)
Other blood	0.9 (0.7–1.1)	1.1 (0.9–1.3)	1.0 (0.9–1.2)	1.2 (1.0–1.4)	1.2 (1.0–1.4)
Eye medications	1.6 (1.5–1.8)	1.5 (1.4–1.6)	1.6 (1.5–1.8)	1.7 (1.5–1.9)	1.7 (1.5–1.9)
Anti-infectives	1.0 (0.9–1.2)	0.9 (0.8–1.1)	1.0 (0.9–1.2)	1.0 (0.9–1.2)	1.0 (0.9–1.2)
Urogenital	1.8 (1.7–2.0)	1.8 (1.6–2.0)	1.7 (1.5–1.9)	1.8 (1.7–2.0)	1.6 (1.5–1.8)
Diuretics	1.3 (1.1–1.4)	1.3 (1.1–1.5)	1.1 (0.9–1.3)	1.1 (0.9–1.3)	0.9 (0.8–1.1)
Contraceptives	1.6 (1.5–1.8)	1.7 (1.5–1.8)	1.7 (1.5–1.9)	1.8 (1.6–1.9)	1.6 (1.5–1.8)
Oral/systemic contraception	1.6 (1.5–1.8)	1.7 (1.5–1.8)	1.7 (1.5–1.9)	1.7 (1.6–1.9)	1.6 (1.4–1.7)
Nutrition, metabolism	1.4 (1.2–1.5)	1.7 (1.1–2.2)	1.6 (1.4–1.8)	1.6 (1.5–1.8)	1.5 (1.4–1.7)
Mineral tonic	0.5 (0.4–0.7)	0.6 (0.3–0.8)	0.5 (0.3–0.7)	0.5 (0.4–0.7)	0.5 (0.4–0.7)
Ear, nose topical	2.3 (2.2–2.5)	1.8 (1.7–2.0)	1.6 (1.4–1.7)	1.6 (1.5–1.9)	0.5 (0.3–0.7)
Topical nasal	1.3 (1.2–1.5)	0.9 (0.7–1.0)	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.7 (0.5–1.0)
Topical otic	1.0 (0.8–1.1)	0.9 (0.8–1.1)	0.9 (0.7–1.0)	0.9 (0.7–1.1)	0.9 (0.8–1.1)
Miscellaneous	0.6 (0.4–0.8)	0.5 (0.3–0.6)	0.3 (0.1–0.6)	0.3 (0.1–0.6)	0.3 (0.1–0.5)

(a) Column will not add to 100 because multiple prescriptions could be written at each encounter. Also only the most frequent medications are included.

Note: CI—confidence interval; NSAID—non-steroidal anti-inflammatory drug.

Table A5.10: Most frequently prescribed generic medications, summary of annual results BEACH 2000-01 to 2004-05

Generic drug	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Amoxicillin	3.2 (2.9-3.5)	2.9 (2.7-3.2)	3.1 (2.8-3.5)	3.3 (3.0-3.6)	3.5 (3.2-3.8)
Paracetamol	3.9 (3.5-4.4)	3.1 (2.7-3.4)	3.1 (2.7-3.6)	2.9 (2.4-3.3)	2.7 (2.4-3.0)
Cephalexin	2.2 (2.0-2.4)	2.0 (1.8-2.2)	1.9 (1.7-2.1)	2.0 (1.8-2.2)	2.4 (2.2-2.6)
Paracetamol/codeine	2.2 (2.0-2.4)	2.2 (2.0-2.4)	2.0 (1.8-2.2)	2.1 (1.9-2.3)	2.0 (1.8-2.2)
Amoxicillin/potass. clavulanate	1.7 (1.4-1.9)	1.6 (1.3-1.8)	1.6 (1.4-1.8)	1.7 (1.5-1.9)	1.7 (1.5-1.9)
Salbutamol	2.1 (1.9-2.3)	2.0 (1.8-2.2)	1.7 (1.5-1.9)	1.5 (1.4-1.7)	1.4 (1.3-1.6)
Atorvastatin	0.9 (0.8-1.0)	1.0 (0.9-1.2)	1.0 (0.9-1.2)	1.2 (1.0-1.3)	1.4 (1.2-1.5)
Temazepam	1.4 (1.3-1.6)	1.3 (1.2-1.5)	1.2 (1.0-1.3)	1.2 (1.1-1.4)	1.1 (1.0-1.3)
Roxithromycin	1.6 (1.4-1.8)	1.4 (1.2-1.6)	1.3 (1.1-1.6)	1.1 (1.0-1.3)	1.1 (0.9-1.4)
Diazepam	1.0 (0.9-1.2)	1.0 (0.8-1.3)	1.0 (0.8-1.2)	1.1 (0.9-1.3)	1.1 (0.9-1.3)
Simvastatin	0.9 (0.7-1.1)	0.9 (0.8-1.1)	0.9 (0.7-1.0)	1.0 (0.9-1.2)	1.1 (0.9-1.3)
Levonorgestrel/ethinyloestradiol	1.2 (1.1-1.4)	1.2 (1.1-1.3)	1.1 (1.0-1.3)	1.2 (1.0-1.3)	1.0 (0.9-1.2)
Tramadol	0.2 (0.0-0.5)	0.7 (0.4-0.9)	1.0 (0.8-1.1)	0.9 (0.8-1.1)	1.0 (0.8-1.2)
Metformin	0.8 (0.6-1.0)	0.9 (0.8-1.1)	0.8 (0.7-1.0)	1.0 (0.8-1.2)	1.0 (0.8-1.1)
Diclofenac sodium systemic	1.2 (0.9-1.4)	0.9 (0.7-1.1)	0.7 (0.5-0.9)	0.8 (0.6-1.0)	1.0 (0.8-1.1)
Chloramphenicol eye	0.9 (0.7-1.0)	0.8 (0.7-0.9)	0.9 (0.8-1.1)	0.9 (0.8-1.0)	0.9 (0.8-1.1)
Warfarin sodium	0.8 (0.6-1.0)	0.9 (0.7-1.1)	0.8 (0.6-1.0)	0.9 (0.7-1.1)	0.9 (0.7-1.2)
Celecoxib	2.1 (1.9-2.4)	1.4 (1.3-1.6)	1.1 (0.9-1.2)	1.0 (0.9-1.1)	0.9 (0.7-1.1)
Atenolol	0.9 (0.7-1.1)	1.0 (0.7-1.2)	0.8 (0.6-1.0)	1.0 (0.8-1.1)	0.9 (0.7-1.1)
Irbesartan	0.8 (0.6-0.9)	0.8 (0.6-0.9)	0.8 (0.7-1.0)	0.9 (0.7-1.0)	0.9 (0.7-1.0)
Influenza virus vaccine	1.5 (0.8-2.2)	1.5 (0.8-2.2)	1.4 (0.6-2.3)	1.2 (0.4-2.0)	0.9 (0.0-1.8)
Fluticasone/salmeterol	0.2 (0.0-0.6)	0.6 (0.4-0.8)	0.9 (0.7-1.1)	0.8 (0.7-1.0)	0.9 (0.7-1.0)

(continued)

Table A5.10 (continued): Most frequently prescribed generic medications, summary of annual results BEACH 2000-01 to 2004-05

Generic drug	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Perindopril	0.6 (0.4-0.8)	0.7 (0.6-0.9)	0.7 (0.5-0.8)	0.7 (0.5-0.9)	0.8 (0.7-1.0)
Meloxicam	N/A	0.0 [†] (0.0-1.2)	0.3 (0.0-0.6)	0.4 (0.2-0.6)	0.8 (0.6-1.0)
Cefaclor monohydrate	1.6 (1.3-2.0)	1.1 (0.8-1.3)	1.0 (0.7-1.3)	0.8 (0.5-1.1)	0.8 (0.4-1.2)
Mometasone	0.7 (0.5-0.8)	0.8 (0.6-0.9)	0.6 (0.5-0.8)	0.5 (0.4-0.7)	0.8 (0.7-1.0)
Ramipril	0.4 (0.2-0.6)	0.6 (0.4-0.8)	0.7 (0.5-0.8)	0.7 (0.6-0.9)	0.8 (0.6-1.0)
Doxycycline hydrochloride	0.9 (0.7-1.1)	0.8 (0.6-1.0)	0.7 (0.5-0.9)	0.7 (0.5-0.9)	0.7 (0.6-0.9)
Betamethasone topical	1.0 (0.9-1.2)	0.9 (0.7-1.0)	0.7 (0.6-0.9)	0.8 (0.7-1.0)	0.7 (0.6-0.9)
Esomeprazole	N/A	N/A	0	0.6 (0.4-0.8)	0.7 (0.6-0.8)
Omeprazole	0.5 (0.3-0.6)	0.8 (0.7-1.0)	0.8 (0.7-1.0)	0.7 (0.6-0.8)	0.6 (0.5-0.8)
Frusemide (furosemide)	0.7 (0.7-0.9)	0.7 (0.5-0.9)	0.7 (0.5-0.9)	0.7 (0.5-0.8)	0.6 (0.4-0.8)
Erythromycin	0.8 (0.6-1.0)	0.6 (0.4-0.8)	0.5 (0.3-0.7)	0.6 (0.3-0.8)	0.5 (0.3-0.7)
Ranitidine	1.0 (0.9-1.2)	0.6 (0.5-0.8)	0.5 (0.3-0.6)	0.4 (0.2-0.6)	0.3 (0.3-0.5)
Rofecoxib	0.1 (0.0-0.8)	1.2 (1.0-1.5)	1.2 (0.9-1.4)	1.0 (0.9-1.2)	0.3 (0.0-0.7)
Total prescribed medications	92.3 (89.9-94.7)	88.0 (85.6-90.4)	84.3 (81.8-86.9)	86.0 (83.6-88.5)	83.4 (81.2-85.5)

(a) Column will not add to 100 because multiple prescriptions could be written at each encounter.

† Rates are reported to one decimal place. This indicates that the rate is <0.05 per 100 encounters.

Note: CI—confidence interval; N/A—not applicable.

Table A5.11: Distribution of prescribed medications by ATC Level 2, summary of annual results BEACH 2000-01 to 2004-05

	2000-01	2001-02	2002-03	2003-04	2004-05
ATC Level 2	Rate per 100 encounters^(a) (95% CI) (n=99,307)	Rate per 100 encounters^(a) (95% CI) (n=96,973)	Rate per 100 encounters^(a) (95% CI) (n=100,987)	Rate per 100 encounters^(a) (95% CI) (n=98,877)	Rate per 100 encounters^(a) (95% CI) (n=94,386)
Analgesics	8.9 (8.4-9.4)	8.5 (8.0-9.0)	8.5 (8.0-9.1)	8.5 (8.0-9.0)	8.3 (7.8-8.7)
Psycholeptics	5.2 (4.9-5.5)	5.1 (4.8-5.5)	4.7 (4.4-5.0)	5.0 (4.7-5.4)	4.9 (4.6-5.2)
Psychoanaleptics	3.1 (2.9-3.3)	3.0 (2.8-3.2)	3.0 (2.8-3.2)	3.3 (3.1-3.5)	3.1 (3.0-3.3)
Anti-epileptics	0.6 (0.4-0.8)	0.6 (0.3-0.8)	0.6 (0.4-0.7)	0.5 (0.3-0.7)	0.5 (0.3-0.8)
Other nervous system drugs	0.7 (0.0-1.4)	0.6 (0.0-1.3)	0.4 (0.0-1.2)	0.3 (0.0-0.8)	0.5 (0.0-1.2)
Antibacterials for systemic use	15.4 (14.8-16.0)	13.9 (13.4-14.4)	13.3 (12.8-13.9)	13.6 (13.1-14.2)	14.0 (13.5-14.6)
Vaccines	3.8 (3.4-4.3)	3.8 (3.4-4.2)	4.2 (3.7-4.6)	3.3 (2.9-3.7)	2.9 (2.4-3.5)
Agents acting on the renin-angiotensin system	4.5 (4.3-4.8)	5.0 (4.7-5.3)	4.9 (4.6-5.2)	5.5 (5.1-5.8)	5.5 (5.2-5.9)
Serum lipid reducing agents	2.4 (2.2-2.6)	2.4 (2.3-2.6)	2.4 (2.2-2.6)	2.8 (2.6-3.0)	3.0 (2.8-3.2)
Calcium channel blockers	2.3 (2.1-2.5)	2.2 (2.0-2.4)	2.0 (1.8-2.2)	2.2 (2.0-2.3)	2.0 (1.8-2.2)
Beta-blocking agents	1.7 (1.5-1.9)	1.8 (1.6-2.0)	1.6 (1.4-1.8)	1.8 (1.6-2.0)	1.7 (1.5-1.8)
Diuretics	1.8 (1.7-2.0)	1.7 (1.5-1.9)	1.6 (1.4-1.8)	1.5 (1.4-1.7)	1.3 (1.2-1.5)
Cardiac therapy	1.2 (1.0-1.4)	1.2 (1.0-1.4)	1.0 (0.7-1.2)	1.0 (0.8-1.3)	0.8 (0.7-1.0)
Drugs for acid related disorders	2.4 (2.2-2.5)	2.5 (2.3-2.7)	2.5 (2.4-2.7)	2.9 (2.7-3.0)	2.7 (2.5-2.9)
Drugs used in diabetes	2.0 (1.7-2.3)	2.2 (1.9-2.5)	1.9 (1.6-2.2)	2.2 (1.9-2.4)	2.1 (1.8-2.3)
Drugs used for functional gastrointestinal disorders	1.0 (0.9-1.2)	0.9 (0.8-1.1)	0.9 (0.7-1.1)	1.0 (0.8-1.1)	0.7 (0.6-0.8)
Anti-diarrhoeals, intestinal anti-inflammatory/anti-infective agents	0.7 (0.5-0.9)	0.6 (0.4-0.8)	0.6 (0.4-0.9)	0.6 (0.4-0.8)	0.6 (0.4-0.7)
Mineral supplements	0.4 (0.3-0.6)	0.5 (0.2-0.7)	0.4 (0.2-0.6)	0.4 (0.3-0.6)	0.4 (0.3-0.6)
Anti-obesity preparations, excluding diet products	0.3 (0.2-0.5)	0.3 (0.1-0.6)	0.4 (0.3-0.6)	0.4 (0.2-0.6)	0.3 (0.0-0.5)
Anti-inflammatory and antirheumatic	5.7 (5.4-6.0)	5.3 (5.1-5.6)	4.8 (4.6-5.1)	4.8 (4.5-5.0)	4.5 (4.2-4.8)

(continued)

Table A5.11 (continued): Distribution of prescribed medications by ATC Level 2, summary of annual results BEACH 2000-01 to 2004-05

	2000-01	2001-02	2002-03	2003-04	2004-05
ATC Level 2	Rate per 100 encounters^(a) (95% CI) (n=99,307)	Rate per 100 encounters^(a) (95% CI) (n=96,973)	Rate per 100 encounters^(a) (95% CI) (n=100,987)	Rate per 100 encounters^(a) (95% CI) (n=98,877)	Rate per 100 encounters^(a) (95% CI) (n=94,386)
Anti-gout preparations	0.4 (0.3-0.6)	0.4 (0.2-0.6)	0.5 (0.3-0.7)	0.5 (0.3-0.6)	0.5 (0.3-0.7)
Drugs for treatment of bone disease	0.2 (0.0-0.4)	0.3 (0.1-0.4)	0.4 (0.2-0.6)	0.4 (0.3-0.6)	0.5 (0.3-0.6)
Drugs for obstructive airway diseases	5.5 (5.2-5.9)	5.1 (4.8-5.5)	4.6 (4.2-4.9)	4.1 (3.9-4.4)	3.8 (3.6-4.1)
Nasal preparations	1.5 (1.3-1.6)	0.9 (0.8-1.1)	0.8 (0.6-1.0)	0.8 (0.6-1.0)	0.8 (0.5-1.0)
Antihistamines for systemic use	0.7 (0.5-1.0)	0.6 (0.1-1.1)	0.6 (0.1-1.1)	0.5 (0.3-0.7)	0.4 (0.2-0.7)
Cough and cold preparations	0.5 (0.1-0.8)	0.4 (0.1-0.8)	0.5 (0.0-1.0)	0.4 (0.0-0.8)	0.4 (0.0-0.9)
Corticosteroids, dermatological preparations	3.1 (2.8-3.3)	2.8 (2.6-3.0)	2.6 (2.5-2.8)	2.6 (2.4-2.8)	2.8 (2.6-2.9)
Antibiotics and chemotherapeutics for dermatological use	0.4 (0.2-0.6)	0.3 (0.2-0.5)	0.4 (0.2-0.5)	0.4 (0.2-0.5)	0.4 (0.3-0.6)
Sex hormones and modulators of the genital system	3.9 (3.7-4.1)	3.8 (3.6-4.0)	3.7 (3.5-4.0)	3.5 (3.3-3.7)	3.1 (2.9-3.3)
Ophthalmologicals	1.7 (1.5-1.8)	1.5 (1.4-1.7)	1.6 (1.5-1.8)	1.7 (1.6-1.8)	1.7 (1.6-1.9)
Otologicals	0.9 (0.8-1.1)	0.9 (0.7-1.0)	0.8 (0.7-0.9)	0.8 (0.7-1.0)	0.8 (0.7-1.0)
Anti-thrombotic agents	1.0 (0.8-1.2)	1.1 (0.9-1.3)	1.1 (0.9-1.3)	1.3 (1.1-1.5)	1.3 (1.1-1.5)
Anti-anaemic preparations	0.9 (0.8-1.1)	0.8 (0.6-0.9)	0.7 (0.6-0.8)	0.9 (0.7-1.0)	0.7 (0.5-0.9)
Corticosteroids for systemic use	1.2 (1.1-1.4)	1.3 (1.2-1.5)	1.1 (0.9-1.2)	1.3 (1.1-1.4)	1.2 (1.1-1.4)
Thyroid therapy	0.5 (0.4-0.7)	0.6 (0.4-0.7)	0.6 (0.4-0.7)	0.6 (0.5-0.8)	0.7 (0.5-0.8)

(a) Column will not add to 100 because multiple prescriptions could be written at each encounter. Also only the most frequent medications are included.

Note: CI—confidence interval; potass—potassium.

Table A5.12: Medications most frequently supplied by GPs, summary of annual results BEACH 2000-01 to 2004-05

	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Generic medication					
Influenza virus vaccine	0.6 (0.0-1.4)	0.9 (0.0-2.1)	0.7 (0.0-0.9)	1.2 (0.0-2.6)	1.2 (0.0-2.9)
Pneumococcal vaccine	0	0.0 [†] (0.0-1.0)	0.1 (0.0-0.9)	0.1 (0.0-0.8)	0.4 (0.0-1.0)
Polio vaccine oral sabin/injection	0.3 (0.0-0.6)	0.3 (0.0-0.7)	0.3 (0.0-0.7)	0.3 (0.1-0.6)	0.4 (0.2-0.7)
Triple antigen(diphtheria/pertussis/tetanus)	0.2 (0.0-0.7)	0.2 (0.0-0.6)	0.1 (0.0-0.6)	0.2 (0.0-0.5)	0.3 (0.0-0.7)
Mumps/measles/rubella vaccine	0.2 (0.0-0.5)	0.2 (0.0-0.5)	0.1 (0.0-0.4)	0.2 (0.0-0.5)	0.3 (0.0-0.5)
Haemophilus B vaccine	0.2 (0.0-0.6)	0.2 (0.0-0.5)	0.2 (0.0-0.6)	0.2 (0.0-0.5)	0.2 (0.0-0.5)
Vitamin B12 (cobalamin)	0.1 (0.0-0.7)	0.1 (0.0-0.7)	0.1 (0.0-0.8)	0.1 (0.0-0.5)	0.2 (0.0-0.6)
ADT/CDT (diphtheria/tetanus) vaccine	0.2 (0.0-0.4)	0.1 (0.0-0.5)	0.1 (0.0-0.5)	0.1 (0.0-0.4)	0.2 (0.0-0.4)
Meloxicam	N/A	0.0 [†] (0.0-1.1)	0.1 (0.0-0.6)	0.2 (0.0-0.7)	0.2 (0.0-0.6)
Diphtheria/pertussis/tetanus/Hep B	0.1 (0.0-0.6)	0.2 (0.0-0.6)	0.2 (0.0-0.7)	0.2 (0.0-0.6)	0.2 (0.0-0.5)
Meningitis vaccine	0	0.0 [†] (0.0-0.9)	0.2 (0.0-0.9)	0.3 (0.0-0.6)	0.2 (0.0-0.5)
Celecoxib	0.3 (0.0-0.7)	0.2 (0.0-0.5)	0.1 (0.0-0.5)	0.1 (0.0-0.4)	0.1 (0.0-0.4)
Hepatitis B vaccine	0.2 (0.0-0.5)	0.1 (0.0-0.5)	0.1 (0.0-0.4)	0.1 (0.0-0.6)	0.1 (0.0-0.6)
Metoclopramide	0.2 (0.0-0.8)	0.1 (0.0-0.4)	0.1 (0.0-0.4)	0.2 (0.0-0.6)	0.1 (0.0-0.4)
Amoxycillin	0.1 (0.0-2.1)	0.1 (0.0-1.6)	0.2 (0.0-1.5)	0.2 (0.0-2.5)	0.1 (0.0-1.1)
Rofecoxib	0	0.3 (0.0-0.5)	0.2 (0.0-0.6)	0.1 (0.0-0.5)	0
Total GP-supplied medications	6.9 (5.7-8.1)	7.6 (6.3-9.0)	9.3 (7.6-11.0)	8.6 (7.4-9.8)	8.1 (7.3-8.9)

(a) Only those medications supplied at a rate of 0.2 per 100 encounters or more in any BEACH year reported here are included.

† Rates are reported to one decimal place. This indicates that the rate is <0.05 per 100 encounters.

Note: CI—confidence interval; N/A—not applicable.

Table A5.13: Most frequently advised over-the-counter medications, summary of annual results BEACH 2000-01 to 2004-05

	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=98,877)	Rate per 100 encounters ^(a) (95% CI) (n=94,386)
Generic medication					
Paracetamol	2.4 (1.8-2.9)	2.1 (1.7-2.6)	2.6 (2.1-3.0)	2.5 (1.9-3.0)	2.3 (1.8-2.8)
Ibuprofen	0.5 (0.2-0.8)	0.5 (0.2-0.8)	0.7 (0.1-1.3)	0.2 (0.0-0.5)	0.5 (0.2-0.9)
Loratadine	0.2 (0.0-0.6)	0.3 (0.0-0.5)	0.3 (0.0-0.6)	0.2 (0.0-0.5)	0.2 (0.0-0.6)
Saline bath/solution/gargle	0	0.1 (0.0-0.6)	0.2 (0.0-0.6)	0.1 (0.0-0.7)	0.2 (0.0-0.7)
Diclofenac diethyl topical	0.2 (0.0-0.6)	0.2 (0.0-0.5)	0.2 (0.0-0.5)	0.2 (0.0-0.6)	0.2 (0.0-0.5)
Fexofenadine	0.1 (0.0-0.5)	0.1 (0.0-0.5)	0.1 (0.0-0.4)	0.1 (0.0-0.5)	0.2 (0.0-0.5)
Simple analgesics	0	0.1 (0.0-1.0)	0	0.1 (0.0-0.9)	0.2 (0.0-0.8)
Clotrimazole topical	0.2 (0.0-0.5)	0.2 (0.0-0.4)	0.2 (0.0-0.4)	0.2 (0.0-0.4)	0.2 (0.0-0.4)
Paracetamol/codeine	0.2 (0.0-0.5)	0.2 (0.0-0.5)	0.1 (0.0-0.5)	0.1 (0.0-0.5)	0.1 (0.0-0.6)
Aspirin	0.1 (0.0-0.5)	0.2 (0.0-0.5)	0.2 (0.0-0.4)	0.2 (0.0-0.5)	0.1 (0.0-0.5)
Chlorpheniramine/pseudoephedrine	0.2 (0.0-0.7)	0.1 (0.0-0.5)	0.1 (0.0-0.7)	0.1 (0.0-0.5)	0.1 (0.0-1.0)
Brompheniramine/phenylephrine	0.2 (0.0-0.7)	0.1 (0.0-0.7)	0.1 (0.0-0.6)	0.1 (0.0-0.7)	0.1 (0.0-0.7)
Pseudoephedrine	0.2 (0.0-0.6)	0.1 (0.0-0.5)	0.1 (0.0-0.6)	0.1 (0.0-0.5)	0
Total advised medications	9.0 (8.1-9.8)	8.9 (8.1-9.6)	10.2 (9.2-11.1)	9.4 (8.6-10.1)	10.1 (9.1-11.0)

(a) Only those medications supplied at a rate of 0.2 per 100 encounters or more in any BEACH year reported here are included.

Note: CI—confidence interval.

Table A5.14: The most frequent clinical treatments, summary of annual results BEACH 2000-01 to BEACH 2004-05

Treatment	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=98,877)	Rate per 100 encounters (95% CI) (n=94,386)
Advice/education*	5.8 (5.1-6.5)	6.3 (5.4-7.1)	6.9 (5.9-7.9)	6.8 (5.9-7.7)	7.0 (6.2-7.8)
Counselling/advice—nutrition/weight*	5.6 (4.9-6.2)	5.5 (5.0-6.0)	5.2 (4.6-5.9)	4.6 (4.1-5.2)	5.3 (4.7-5.9)
Advice/education—treatment*	5.9 (5.1-6.6)	5.1 (4.5-5.7)	4.2 (3.6-4.9)	4.4 (3.7-5.0)	4.6 (4.0-5.1)
Counselling—problem*	3.4 (2.8-3.9)	4.7 (3.8-5.5)	5.5 (4.7-6.3)	4.7 (3.8-5.5)	4.2 (3.3-5.0)
Advice/education—medication*	2.6 (2.2-3.0)	2.8 (2.5-3.2)	2.5 (2.1-2.8)	3.4 (3.0-3.8)	3.4 (2.9-3.8)
Counselling—psychological*	2.8 (2.5-3.2)	3.2 (2.8-3.5)	2.9 (2.6-3.2)	2.9 (2.6-3.1)	3.2 (2.9-3.5)
Counselling/advice—exercise*	2.2 (1.7-2.6)	2.1 (1.6-2.5)	1.6 (1.2-2.0)	1.5 (1.1-1.9)	1.9 (1.4-2.3)
Sickness certificate	1.1 (0.4-1.8)	1.1 (0.5-1.6)	1.3 (0.8-1.8)	1.0 (0.6-1.4)	1.7 (1.3-2.1)
Reassurance, support	1.5 (1.1-2.0)	1.5 (1.0-1.9)	1.4 (1.0-1.7)	1.5 (1.0-1.9)	1.6 (1.2-1.9)
Administrative procedure*	1.5 (1.2-1.7)	1.5 (1.3-1.8)	1.6 (1.3-1.8)	1.8 (1.5-2.1)	1.3 (1.1-1.5)
Counselling/advice—smoking*	0.8 (0.6-1.0)	0.8 (0.6-1.0)	0.7 (0.4-0.9)	0.6 (0.4-0.9)	0.8 (0.6-1.0)
Counselling/advice—alcohol*	0.4 (0.2-0.7)	0.4 (0.2-0.6)	0.4 (0.1-0.6)	0.4 (0.2-0.5)	0.5 (0.2-0.7)
Counselling/advice—lifestyle*	0.3 (0.0-0.9)	0.4 (0.0-1.0)	0.5 (0.0-1.5)	0.3 (0.0-0.8)	0.4 (0.0-1.0)
Counselling/advice—prevention*	0.3 (0.0-0.6)	0.3 (0.0-0.6)	0.3 (0.0-0.8)	0.4 (0.0-0.8)	0.4 (0.1-0.8)
Observe/wait*	0.7 (0.0-2.0)	0.3 (0.0-0.7)	0.3 (0.0-0.7)	0.3 (0.0-0.7)	0.4 (0.0-0.7)
Family planning*	0.3 (0.1-0.6)	0.3 (0.1-0.6)	0.4 (0.1-0.6)	0.4 (0.2-0.6)	0.4 (0.2-0.6)
Counselling/advice—health/body*	0.4 (0.0-0.8)	0.3 (0.1-0.6)	0.3 (0.0-0.8)	0.3 (0.0-0.7)	0.4 (0.1-0.6)
Total clinical treatments	37.2 (35.1-39.3)	38.1 (36.1-40.1)	37.2 (35.0-39.4)	36.6 (34.5-38.8)	39.2 (37.1-41.4)

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 3, <www.aihw.gov.au/publications/index.cfm>).

Note: CI—confidence interval.

Table A5.15: The most frequent procedural treatments, summary of annual results BEACH 2000-01 to BEACH 2004-05

Treatment	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=98,877)	Rate per 100 encounters (95% CI) (n=94,386)
Excision/removal tissue/biopsy/destruction/debridement/cauterisation*	2.6 (2.4-2.9)	2.7 (2.4-3.0)	2.9 (2.6-3.1)	3.1 (2.6-3.7)	3.3 (2.9-3.7)
Physical medicine/rehabilitation*	2.0 (1.6-2.4)	2.2 (1.8-2.6)	2.1 (1.6-2.6)	1.7 (1.3-2.0)	2.0 (1.5-2.5)
Dressing/pressure/compression/tamponade*	1.8 (1.6-2.0)	1.8 (1.6-2.0)	2.0 (1.8-2.2)	1.8 (1.6-2.1)	2.0 (1.8-2.2)
Local injection/infiltration*	0.2 (0.0-0.5)	1.2 (0.5-1.8)	1.5 (1.2-1.8)	1.6 (1.3-1.9)	2.0 (1.6-2.3)
Other therapeutic procedures/surgery NEC*	1.1 (0.4-1.9)	1.4 (0.8-2.0)	1.2 (0.8-1.6)	1.1 (0.6-1.7)	1.2 (0.3-2.1)
Incision/drainage/flushing/aspiration/removal body fluid*	1.1 (0.9-1.2)	1.2 (1.0-1.3)	1.1 (1.0-1.3)	1.2 (1.0-1.3)	1.0 (0.9-1.2)
Pap smear*	0.8 (0.6-1.1)	0.9 (0.6-1.1)	1.1 (0.8-1.4)	1.1 (0.7-1.5)	1.0 (0.6-1.3)
Repair/fixation—suture/cast/prosthetic device (apply/remove)*	1.0 (0.8-1.1)	0.9 (0.7-1.0)	0.9 (0.7-1.0)	0.8 (0.7-1.0)	0.9 (0.8-1.0)
Physical function test*	0.5 (0.0-1.0)	0.4 (0.0-0.9)	0.5 (0.0-1.1)	0.4 (0.1-0.7)	0.4 (0.1-0.7)
Other preventive procedures/high-risk medication, condition*	0.0 [†]	0.0 [†]	0.2 (0.0-0.6)	0.3 (0.0-0.7)	0.3 (0.0-0.7)
Electrical tracings*	0.4 (0.1-0.6)	0.3 (0.0-0.5)	0.3 (0.1-0.6)	0.3 (0.1-0.6)	0.3 (0.1-0.6)
Urine test*	0.2 (0.0-0.5)	0.2 (0.0-0.6)	0.3 (0.0-0.6)	0.3 (0.0-0.6)	0.3 (0.0-0.6)
Test; glucose	0.2 (0.0-0.6)	0.2 (0.0-0.7)	0.2 (0.0-0.6)	0.3 (0.0-0.6)	0.2 (0.0-0.6)
Pregnancy test*	0.2 (0.0-0.5)	0.3 (0.0-0.5)	0.2 (0.0-0.4)	0.2 (0.0-0.5)	0.2 (0.0-0.4)
Total procedural treatments	12.2 (11.6-12.8)	13.8 (13.1-14.5)	14.6 (13.9-15.3)	14.7 (14.0-15.5)	15.5 (14.6-16.4)

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 3, <www.aihw.gov.au/publications/index.cfm>).

† Rates are reported to one decimal place. This indicates that the rate is <0.05 per 100 encounters. The sample size is too small to calculate confidence intervals.

Note: CI—confidence interval.

Table A5.16: The most frequent referrals, summary of annual results BEACH 2000-01 to BEACH 2004-05

	2000-01	2001-02	2002-03	2003-04	2004-05
	Rate per 100 encounters^(a) (95% CI) (n=99,307)	Rate per 100 encounters^(a) (95% CI) (n=96,973)	Rate per 100 encounters^(a) (95% CI) (n=100,987)	Rate per 100 encounters^(a) (95% CI) (n=98,877)	Rate per 100 encounters^(a) (95% CI) (n=94,386)
At least one referral	9.9 (9.6–10.3)	10.0 (9.6–10.4)	10.6 (10.2–11.0)	11.0 (10.5–11.5)	10.9 (10.5–11.3)
Referrals	10.4 (10.0–10.8)	10.5 (10.1–10.9)	11.1 (10.7–11.6)	11.6 (11.1–12.1)	11.5 (11.1–12.0)
Specialist	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.7 (7.3–8.0)	7.9 (7.5–8.2)	7.7 (7.4–8.0)
Referral; ophthalmologist	0.7 (0.5–0.8)	0.8 (0.6–0.9)	0.7 (0.6–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)
Referral; surgeon	0.7 (0.6–0.8)	0.8 (0.6–0.9)	0.7 (0.6–0.9)	0.8 (0.7–1.0)	0.8 (0.7–0.9)
Referral; orthopaedic surgeon	0.7 (0.5–0.8)	0.7 (0.6–0.8)	0.8 (0.6–0.9)	0.7 (0.6–0.8)	0.7 (0.6–0.8)
Allied health service	2.3 (2.1–2.5)	2.3 (2.1–2.5)	2.5 (2.3–2.8)	2.6 (2.4–2.9)	2.7 (2.5–2.9)
Referral; physiotherapy	1.0 (0.8–1.1)	0.9 (0.7–1.1)	1.1 (0.8–1.3)	1.0 (0.9–1.2)	1.1 (0.9–1.2)
Referral; podiatrist/chiropracist	0.1 (0.0–0.4)	0.2 (0.0–0.4)	0.2 (0.0–0.4)	0.2 (0.0–0.4)	0.2 (0.0–0.4)
Referral; psychologist	0.2 (0.0–0.4)	0.2 (0.0–0.4)	0.2 (0.0–0.4)	0.2 (0.0–0.5)	0.2 (0.0–0.5)
Hospital	0.5 (0.3–0.7)	0.4 (0.3–0.6)	0.6 (0.3–0.8)	0.6 (0.3–0.8)	0.5 (0.3–0.7)
Emergency department	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.2 (0.0–0.5)	0.2 (0.0–0.4)
Other medical services ⁺	NAv	NAv	NAv	0.1 (0.0–0.6)	0.1 (0.0–0.6)
Other referrals	0.1 (0.0–0.6)	0.3 (0.0–0.6)	0.3 (0.0–0.5)	0.3 (0.0–0.6)	0.3 (0.1–0.6)

+ The 'other medical services' grouping was introduced in 2003-04, previously these were grouped in the 'other referrals' group.

Note: CI—confidence interval; NAv—not available.

Table A5.17: Number of encounters where pathology, imaging ordered, summary of annual results BEACH 2000-01 to 2004-05

	2000-01	2001-02	2002-03	2003-04	2004-05
	Per cent of encounters (95% CI) (n=99,307)	Per cent of encounters (95% CI) (n=96,973)	Per cent of encounters (95% CI) (n=100,987)	Per cent of encounters (95% CI) (n=98,877)	Per cent of encounters (95% CI) (n=94,386)
No tests ordered	80.7 (80.1–81.3)	80.8 (80.2–81.4)	79.7 (79.0–80.3)	79.2 (78.5–79.9)	78.8 (78.2–79.5)
At least one pathology test ordered	13.8 (13.3–14.3)	14.0 (13.5–14.5)	14.7 (14.2–15.3)	15.5 (14.9–16.1)	15.7 (15.2–16.3)
At least one imaging ordered	6.8 (6.5–7.1)	6.9 (6.6–7.2)	7.5 (7.1–7.8)	7.2 (6.9–7.5)	7.3 (7.0–7.6)

Note: CI—confidence interval.

Table A5.18: Distribution of pathology orders across pathology groups, summary of annual results BEACH 2000-01 to 2003-04

	2000-01 ^(a)	2001-02	2002-03	2003-04	2004-05
Pathology test ordered	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=97,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=98,877)	Rate per 100 encounters (95% CI) (n=94,386)
Chemistry	15.7 (14.8–16.5)	16.5 (15.6–17.3)	17.7 (16.8–18.6)	19.1 (18.1–20.1)	20.4 (19.5–21.4)
Haematology	5.8 (5.5–6.2)	6.2 (5.8–6.5)	6.3 (5.9–6.6)	6.8 (6.4–7.2)	7.0 (6.6–7.3)
Microbiology	4.6 (4.3–4.9)	4.9 (4.5–5.2)	5.1 (4.8–5.5)	5.3 (4.9–5.7)	5.2 (4.8–5.6)
Cytology	1.5 (1.2–1.8)	1.6 (1.3–1.8)	1.7 (1.4–1.9)	1.8 (1.4–2.1)	1.6 (1.3–2.0)
Other NEC	0.8 (0.4–1.1)	0.7 (0.5–0.9)	0.8 (0.4–1.1)	0.8 (0.5–1.1)	0.8 (0.5–1.2)
Infertility/pregnancy	0.3 (0.0–0.6)	0.3 (0.1–0.5)	0.3 (0.1–0.5)	0.2 (0.0–0.5)	0.3 (0.0–0.6)
Tissue pathology	0.5 (0.2–0.7)	0.5 (0.1–0.8)	0.5 (0.2–0.8)	1.8 (1.4–2.1)	0.8 (0.3–1.2)
Immunology	0.5 (0.2–0.8)	0.5 (0.3–0.7)	0.5 (0.2–0.7)	0.7 (0.2–1.2)	0.5 (0.3–0.8)
Simple test; other	0.1 (0.0–0.5)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.1 (0.0–0.4)
Total pathology tests	29.7 (28.4–30.9)	31.0 (29.7–32.4)	32.9 (31.5–34.4)	35.2 (33.7–36.7)	36.7 (35.2–38.2)

(a) Data collection and coding method changed at the end of the third year of BEACH (2000-01). Year 3 data were re-coded to be comparable with years 4 to 6.

Note: CI—confidence interval; NEC—not elsewhere classified.

Table A5.19: Most frequent imaging tests ordered BEACH 1999–00 and 2003–04

	2000–01	2001–02	2002–03	2003–04	2004–05
Imaging test ordered	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=98,877)	Rate per 100 encounters (95% CI) (n=94,386)
Diagnostic radiology	4.8 (4.6–5.1)	4.6 (4.4–4.8)	5.1 (4.9–5.4)	4.6 (4.3–4.8)	4.5 (4.3–4.7)
Ultrasound	2.1 (2.0–2.3)	2.5 (2.3–2.7)	2.6 (2.5–2.8)	2.7 (2.5–2.8)	2.7 (2.5–2.8)
Computerised tomography	0.7 (0.6–0.8)	0.8 (0.6–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	1.0 (0.9–1.2)
Nuclear medicine imaging	0.0 [‡] (0.0–0.4)	0.0 [‡] (0.0–0.4)	0.0 [‡] (0.0–0.4)	0.1 (0.0–0.3)	0.1 (0.0–0.3)
Magnetic resonance imaging	0.0 [‡] (0.0–0.4)	0.0 [‡] (0.0–0.5)	0.0 [‡] (0.0–0.6)	0.0 [‡] (0.0–0.5)	0.0 [‡] (0.0–0.5)
Total imaging tests	7.7 (7.3–8.0)	7.9 (7.6–8.2)	8.6 (8.2–9.0)	8.2 (7.8–8.6)	8.3 (8.0–8.6)

[‡] Rates are reported to one decimal place. This indicates that the rate is <0.05 per 100 encounters.

Note: CI—confidence interval.

Table A5.20: Comparative results for patient (aged 18 years and over) risk factors, 2000-01 to 2004-05

	2000–01	2001–02	2002–03	2003–04	2004–05
Risk factor	Per cent (95% CI)	Per cent (95% CI)	Per cent (95% CI)	Per cent (95% CI)	Per cent (95% CI)
Adult					
Obese	20.2 (19.5–20.8)	21.4 (20.7–22.1)	20.9 (20.2–21.5)	22.0 (21.4–22.7)	22.4 (21.7–23.1)
Overweight	34.1 (33.4–34.7)	33.5 (32.9–34.1)	33.8 (33.2–34.5)	34.5 (33.8–35.1)	34.6 (33.9–35.2)
Current daily smoker	19.3 (18.5–20.1)	18.4 (17.7–19.1)	17.2 (16.5–17.9)	17.6 (16.8–18.3)	18.0 (17.2–18.7)
At-risk alcohol level	24.1 (23.3–24.9)	26.0 (25.1–26.8)	26.2 (25.4–27.1)	26.7 (25.8–27.6)	26.4 (25.5–27.3)
Children (aged 2–17 years)					
Obese	13.6 (11.0–16.2)	13.0 (10.7–15.3)	14.1 (11.4–16.8)	13.2 (10.5–16.0)	12.1 (10.7–13.6)
Overweight	17.8 (16.2–19.4)	17.6 (15.9–19.3)	18.1 (16.3–19.8)	19.0 (17.0–21.0)	18.1 (16.7–19.4)

Note: CI—confidence interval.

Appendix 6: Dissemination of results from the BEACH program

A full list of BEACH publications is also available from the Family Medicine Research Centre website: <www.fmrc.org.au/publications/>.

BOOKS – GENERAL PRACTICE SERIES (BEACH) ISSN 1442-3022

- Britt H, Miller GC, Knox S, Charles J, Pan Y, Henderson J, Bayram C, Valenti L, Ng A, O'Halloran J 2005. General practice activity in Australia 2004–05. AIHW Cat. No. GEP 18. Canberra: Australian Institute of Health and Welfare (General Practice Series No. 18).
- Knox S, Britt H, Pan Y, Miller GC, Bayram C, Valenti L, Charles J, Henderson J, Ng A, O'Halloran J 2005. Locality matters: the influence of geography on general practice activity in Australia 1998–2004. AIHW Cat. No. GEP 17. Canberra: Australian Institute of Health and Welfare (General Practice Series No. 17).
- Britt H, Miller GC, Knox S, Charles J, Valenti L, Pan Y, Henderson J, Bayram C, O'Halloran J, Ng A 2004. General practice activity in Australia 2003–04. AIHW Cat. No. GEP 16. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 16.
- Britt H, Miller GC, Knox S, Charles J, Valenti L, Bayram C, O'Halloran J, Henderson J, Pan Y, Harrison C 2004. General practice activity in the states and territories of Australia 1998–2003. AIHW Cat. No. GEP 15. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 15.
- Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J et al. 2003. General practice activity in Australia 2002–03. AIHW Cat. No. GEP 14. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 14.
- Britt H, Knox S, Miller GC 2003. Changes in pathology ordering by GPs in Australia 1998–2001. AIHW Cat. No. GEP 13. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 13.
- O'Halloran J, Britt H, Valenti L, Harrison C, Pan Y 2003. Older patients attending general practice in Australia 2000–02. AIHW Cat. No. GEP 12. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 12.
- Bayram C, Britt H, Kelly Z, Valenti L 2003. Male consultations in general practice in Australia 1999–00. AIHW Cat. No. GEP 11. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 11.
- Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J et al. 2002. General practice activity in Australia 2001–02. AIHW Cat. No. GEP 10. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 10.
- Henderson J, Pan Y, Britt H, Charles J, Miller GC, Knox S 2002. Cardiovascular problems and risk behaviours among patients at general practitioner encounters in Australia 1998–00. AIHW Cat. No. GEP 9. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 9.
- Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J et al. 2001. General practice activity in Australia 2000–01. AIHW Cat. No. GEP 8. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 8.
- Britt H, Miller GC, Valenti L 2001. 'It's different in the bush': a comparison of general practice activity in metropolitan and rural areas of Australia 1998–2000. AIHW Cat. No. GEP 6. Canberra: Australian Institute of Health and Welfare, General Practice Series No. 6.

Britt H, Miller GC, Knox S 2001. Imaging orders by general practitioners in Australia 1999-00. AIHW Cat. No. GEP 7. Canberra: Australian Institute of Health and Welfare, General Practice Series No 7.

Britt H, Miller GC, Charles J, Knox S, Sayer GP, Valenti L et al. 2000 General practice activity in Australia 1999-2000. AIHW Cat. No. GEP 5 Canberra: Australian Institute of Health and Welfare, General Practice Series No. 5.

Sayer GP, Britt H, Horn F, Bhasale A, McGeechan K, Charles J et al. 2000. Measures of health and health care delivery in general practice in Australia. AIHW Cat. No. GEP 3. Canberra: Australian Institute of Health and Welfare, General Practice Series no. 3.

Britt H, Miller GC, McGeechan K, Sayer GP 1999 Pathology ordering by general practitioners in Australia 1998. AIHW Cat. No. GEP 4. Canberra: Department of Health and Aged Care.

Britt H, Sayer GP, Miller GC, Charles J, Scahill S, Horn F et al. 1999. General practice activity in Australia 1998-99. AIHW Cat. No. GEP 2. Canberra: Australian Institute of Health and Welfare, General Practice Series no. 2.

Britt H, Sayer GP, Miller GC, Charles J, Scahill S, Horn F et al. 1999. BEACH Bettering the Evaluation and Care of Health: a study of general practice activity, six-month interim report. AIHW Cat. No. GEP 1. Canberra: Australian Institute of Health and Welfare, General Practice Series no. 1.

OTHER BOOKS

Senes S, Britt H 2001. A general practice view of cardiovascular disease and diabetes in Australia. AIHW Cat. No. CVD 17. Canberra: Australian Institute of Health and Welfare, Cardiovascular Disease Series No. 18.

CONTRIBUTIONS TO BOOKS

Australian Institute of Health and Welfare 2004. Australia's health 2004: the ninth biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra, AIHW.

Australian Institute of Health and Welfare 2002. Australia's health 2002: the eighth biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

Australian Institute of Health and Welfare 2000. Australia's health 2000: the seventh biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

Commonwealth Department of Health and Aged Care 2000. General practice in Australia: 2000. Britt H, contributor. Canberra: DHAC.

Australian Institute of Health and Welfare 1998. Australia's health 1998: the sixth biennial health report of the Australian Institute of Health and Welfare. Britt H, contributor. Canberra: AIHW.

REFEREED ARTICLES IN RECOGNISED JOURNALS

Britt HC, Valenti L, Miller GC 2005. Determinants of consultation length in Australian general practice. *Med J Aust* 183(2):68-71.

Harrison CM, Britt HC 2005. Antidepressant use in children: a less depressing story [letter]. *Med J Aust* 182(2):92.

- Harris MF, Furler J, Valenti L, Harris E, Britt H 2004. Matching care to need in general practice: A secondary analysis of Bettering the Evaluation and Care of Health (BEACH) data. *Australian Journal of Primary Health* 10(3):151-155.
- Knox SA, Chondros P 2004. Observed intra-cluster correlation coefficients in a cluster survey sample of patient encounters in general practice in Australia. *BMC Med Res Methodol* 4(1):30.
- O'Halloran J, Britt H, Valenti L, Harrison C, Pan Y, Knox S et al. 2004. Encounters with older patients in Australian general practice. *Aust Fam Physician* 33(10):776.
- Gruen RL, Knox S, Carson P, O'Rourke IC, Britt H, Bailie RS 2004. The demand for surgery: an analysis of referrals from Australian general practitioners. *ANZ J Surg* 74(10):863-868.
- Harrison CM, Britt H 2004. The rates and management of psychological problems in Australian general practice. *Aust N Z Journ Psychiatry* 38(10):781-788
- Caldwell TM, Jorm AF, Jorm S, Knox S, Braddock KBG, Britt H 2004. General practice encounters in psychological problems in rural, remote and metropolitan areas in Australia. *Aust N Z Journ Psychiatry* Oct;38(10):774-780.
- Miller G, Britt H, Pan Y, Knox S 2004. Relationship between general practitioner certification and characteristics of care. *Med Care* Aug;42(8):770-778.
- O'Halloran J, Britt H 2004. General practice encounters with older Australians. *Australas J Ageing* 23(1):7-12.
- Pegram RW, Valenti L 2004. Factors influencing billing status in general practice (letter). *Med J Aust Jul;181(2):115.*
- Johnston VJ, Britt H, Pan Y, Mindel A 2004. The management of sexually transmitted infections by Australian general practitioners. *Sex Transm Infect* Jun;80(3):212-215.
- Gruen RL, Knox S, Britt H, Bailie RS 2004. The Surgical Nosology In Primary-care Settings (SNIPS): a simple bridging classification for the interface between primary and specialist care. *BMC Health Serv Res* May;4(1):8.
- O'Halloran J, Miller GC, Britt H 2004. Defining chronic conditions for primary care with ICPC-2. *Fam Pract* Aug;21(4):381-386.
- Britt H, Valenti L, Miller GC, Farmer J 2004. Determinants of GP billing in Australia: content and time. *Med J Aust Jul;181(2):100-104.*
- Charles J, Britt H, Valenti L 2004. The evolution of the general practice workforce in Australia, 1991-2003. *Med J Aust Jul;181(2):85-90.*
- Charles J, Pan Y, Britt H 2004. Trends in childhood illness and treatment in Australian general practice, 1971-2001. *Med J Aust Mar;180(5):216-219.*
- Henderson J, Knox S, Pan Y, Britt H 2004. Changes in asthma management in Australian general practice. *Primary Care Respiratory Journal* Sep;13(3):138-143.
- Knox SA, Britt H 2004. The contribution of demographic and morbidity factors to self-reported visit frequency of patients: a cross-sectional study of general practice patients in Australia. *BMC Fam Pract* Aug;5(1):17.
- Charles J, Valenti L, Britt H 2003. GP visits by health care card holders. A secondary analysis of data from Bettering the Evaluation and Care of Health (BEACH), a national study of general practice activity in Australia. *Aust Fam Physician* 32(1-2):85-8, 94.
- Bridges-Webb C, Wolk J, Britt H, Pond D 2003. The management of dementia in general practice. A field test of guidelines. *Aust Fam Physician* 32(4):283-285

Harrison CM, Britt HC 2003. Prescriptions for antipsychotics in general practice (letter). *Med J Aust* 2003; 178(9):468-469.

McManus P, Mant A, Mitchell P, Britt H, Dudley J 2003. Use of antidepressants by general practitioners and psychiatrists in Australia. *Aust N Z J Psychiatry* 37(2):184-189.

Britt H, Valenti L, Miller G 2002. Time for care. Length of general practice consultations in Australia. *Aust Fam Physician* 31(9):876-880.

Gruen RL, Knox S, Britt H 2002. Where there is no surgeon: the effect of specialist proximity on general practitioners' referral rates. *Med J Aust* 177(2):111-115.

Knox SA, Britt H 2002. A comparison of general practice encounters with patients from English-speaking and non-English-speaking backgrounds. *Med J Aust* 177(2):98-101.

Britt HC, Miller GC 2000. The BEACH study of general practice. *Med J Aust* 173(2):63-64.

OTHER PUBLICATIONS IN REFEREED JOURNALS

Charles J, Britt H, Ng A 2005. Management of growth delay in patients aged less than 6 years. *Aust Fam Physician* 34(9):714-715.

Valenti L, Charles J, Britt H 2005. Passive smoke in Australian homes: 1999 to 2004 [letter]. *Aust N Z J Public Health* 29(4):387-388.

Charles J, Ng A, Britt H 2005. Presentations of headache in Australian general practice. *Aust Fam Physician* 34(8):618-619.

Charles J, Britt H, Ng A 2005. Management of inflammatory skin conditions in Australian general practice. *Aust Fam Physician* 34(5):316-317.

Charles J, Britt H, Ng A 2005. Management of cardiovascular conditions in Australian general practice. *Aust Fam Physician* 34(6):410-411.

Charles J, Ng A, Britt H 2005. Presentations of shortness of breath in Australian general practice. *Aust Fam Physician* 34(7):520-521.

Britt H, Valenti L, Miller G, Charles J 2005. Presentations of diarrhoea in Australian general practice. *Aust Fam Physician* 34(4):218-219.

Britt H 2005. Adolescent mental health: Reply [letter]. *Aust Fam Physician* 34(4):215-216.

Charles J, Pan Y, Britt H 2005. Management of infertility in Australian general practice. *Aust Fam Physician* 34(3):104-105.

Charles J, Ng A, Britt H, Pan Y, Miller GC, Valenti L et al. 2005. The treatment of adolescents in Australian general practice. *Aust Fam Physician* 34(1/2):8-9.

Bayram C, Pan Y, Valenti L, Britt H, Charles J, Miller GC et al. 2004. Current status of hormone therapy in general practice in Australia. *Aust Fam Physician* 33(11):872-873.

Britt H, Valenti L, Miller G, Bayram C, Charles J, Knox S et al. 2004. Presentations of abdominal pain in Australian general practice. *Aust Fam Physician* 33(12):968-969.

Britt H, Pan Y, Miller GC, Valenti L, Charles J, Knox S et al. 2004. Presentations of 'itch' in Australian general practice. *Aust Fam Physician* 33(7):488.

Charles J, Harrison C, Britt H, Pan Y, Miller GC, Valenti L et al. 2004. General practitioners in teaching practices. *Aust Fam Physician* 33(9):682.

Britt H 2003. BEACH – bettering the evaluation and care of health: a continuous national study of general practice activity. *Commun Dis Intell* 27(3):391-393.

Britt H, Miller G 2003. General practice medical records (correspondence in reply). *Aust Fam Physician* 24:2250.

Britt H, Miller GC, Knox S, Charles J, Valenti L, Henderson J et al 2003. Bettering the Evaluation And Care of Health 2001–2002 (summary of results). *Aust Fam Physician* 32(1/2):59–63.

Britt H 1998. BEACH Bettering the evaluation And Care of Health. *Fam Pract Wonca News* 24(4):vii-viii.

RELATED PUBLICATIONS

Britt H, Miller G, Sayer GP, Sedgwick D 1999. Comparison of practice patterns using Health Insurance Commission data for GPs who have completed the RACGP Training Program and those who have not. Melbourne: The Royal Australian College of General Practitioners.

Britt H, Angelis M, Harris E 1998. The reliability and validity of doctor-recorded morbidity data in active data collection systems. *Scand J Prim Health Care* 16:50–5.

Britt H 1998. Reliability of central coding of patient reasons for encounter in general practice, using the International Classification of Primary Care. *Informatics* May:3–7.

Britt H 1997. A measure of the validity of the ICPC in the classification of reasons for encounter. *Informatics* November:8–12.

Britt H, Meza RA, Del Mar C 1996. Methodology of morbidity and treatment data collection in general practice in Australia: a comparison of two methods. *Fam Pract* 13(5):462–7.

Britt H, Miller G, Charles J, Sayer GP, Marshall P, Bhasale A et al. 1996. A study of general practitioner and gastroenterologist management of upper gastrointestinal problems and symptoms: Final Report to Astra Pharmaceuticals Pty Ltd . Sydney, Family Medicine Research Unit, University of Sydney.

Meza RA, Angelis M, Britt H, Miles DA, Seneta E, Bridges-Webb C 1995. Development of sample size models for national general practice surveys. *Aust J Pub Health* 19(1):34–40.

Britt H, Harris M, Driver B, Bridges-Webb C, O’Toole B, Neary S 1992. Reasons for encounter and diagnosed health problems: convergence between doctors and patients. *Fam Pract* 9:191–4.

Bridges-Webb C, Britt H, Miles DA, Neary S, Charles J, Traynor V 1992. Morbidity and treatment in general practice in Australia 1990–1991. *Med J Aust* 157(19 Oct Spec Sup):S1–S56.

Driver B, Britt H, O’Toole B, Harris M, Bridges-Webb C, Neary S 1991. How representative are patients in general practice morbidity surveys? *Fam Pract* 8:261–8.

PUBLISHED FULL LENGTH CONFERENCE PAPERS

Britt H, Pan Y, Henderson J, Miller GC 2002. The prevalence of cardiovascular disease in general practice in Australia. Presented at Health Outcomes 2002: Current Challenges and Future Frontiers; 17 Jul 2002; Canberra.

Henderson J, Pan Y, Britt H 2002. Asthma management in general practice. Presented at Health Outcomes 2002: Current Challenges and Future Frontiers; 17 Jul 2002; Canberra.

Britt H, Miller GC, Valenti L 2001. ‘It’s different in the bush’: a comparison of general practice activity in metropolitan and rural areas of Australia 1998–2000. Presented at the 6th National Rural Health Conference; 7 Apr 2001; Canberra.

THESES AND TREATISES

O'Halloran J 2002. Aged patient encounters in the general practice setting. Bachelor of Applied Science, Health Information Management (Honours) thesis. Sydney: University of Sydney.

Sutton C 2001. Male encounters with general practitioners in Australia 1999–00. Bachelor of Applied Science, Health Information Management (Honours) thesis. Sydney: University of Sydney.

Charles J 1999. Changes in morbidity and its management between 1991 and 1997 in general practice in Victoria. Master of Science in Medicine thesis. Sydney: University of Sydney.

Kelly Z 1999. Management of upper gastrointestinal problems for patients presenting to general practice in Australia 1998–99. Bachelor of Applied Science, Health Information Management (Honours) thesis. Sydney: University of Sydney.

Sedgwick D 1998. The prescribing of antibiotics for upper respiratory infections in general practice and its relationship to socio-economic status. Master of Public Health thesis. Sydney: University of Sydney.

SAND ABSTRACTS ISSN 1444-9072

AIHW GP Statistics and Classification Unit 2000. Allergic rhinitis. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 1. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Anxiety/stress, consultation time, level of education. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 2. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Asthma. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 3. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Cardiovascular disease. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 4. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Depression. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 5. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Employment status and workers' compensation claims. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 6. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Health services utilisation, lifestyle status and chronicity. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 7. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Hormone replacement therapy (HRT). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 8. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Influenza and absenteeism. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 9. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Length of consultation; after hours arrangements; co-morbidity. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 10. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Patient employment status and occupation. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 11. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Smoking and passive smoking in general practice patients. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 12. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2000. Perceived stress. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 13. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Co-medications. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 14. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Lipid lowering medication. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 15. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Effect of day and time of GP visit on billing method. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 16. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Private prescription products. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 17. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Drugs for the treatment of peptic ulcer and reflux. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 18. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Osteoporosis. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 19. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Screening and management of blood cholesterol. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 20. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Diabetes – prevalence, management and screening. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 21. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Asthma – prevalence, severity and management. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 22. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Depression. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 23. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2001. Gastro-oesophageal reflux disease (GORD) in general practice patients. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 24. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Prevalence of diabetes, medications and control. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 25. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Prevalence of diagnosed hypertension and difficulties in treatment. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 26. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Prevalence and management of influenza. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 27. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Prevalence of Alzheimer's disease and dementia. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 28. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Non-steroidal anti-inflammatory drugs (NSAIDs) and acid suppressant use. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 29. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Lipid lowering medications and coronary heart disease. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 30. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Prevalence and severity of chronic heart failure. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 31. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Patient use of after-hours medical services. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 32. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Prevalence and management of cardiovascular risk factors. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 33. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Gastro-oesophageal reflux disease (GOED). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 34. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Smoking status of adults and their attempts to quit. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 35. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Patient use of complimentary therapies. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 36. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2002. Prevalence of common morbidities in patients encountered in general practice. Sydney: University of Sydney, SAND abstracts from the BEACH program No. 37. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. SAND Method: 2002-03. Sydney: University of Sydney, SAND abstracts from the BEACH program. URL: <http://www.fmrc.org.au/Beach/Abstracts/SANDmethod-2003.pdf>.

AIHW GP Statistics and Classification Unit 2003. Prevalence of chronic heart failure, its management and control. Pan Y (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 38. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Severity of asthma, medications and management. Bayram C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 39. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Type 2 diabetes mellitus, prevalence and management. Henderson J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 40. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Time of visit and billing status. Valenti L (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 41. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Prevalence and management of chronic pain. Henderson J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 42. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Initiation and purpose of pathology orders. Pan Y (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 43. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Severity of illness. Miller G (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 44. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Diabetes mellitus prevalence, management and risk factors. Charles J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 45. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Coronary heart disease, risk factors and lipid lowering medication. Charles J (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 46. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Management of depression and anxiety. Harrison C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 47. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Asthma prevalence and management. Bayram C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 48. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Health status and management of patients on non-steroidal anti-inflammatory drugs. Knox S (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 49. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Risk factors of patients on lipid lowering medications. Britt H (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 50. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Use of proton pump inhibitors for gastrointestinal problems. Miller G (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 51. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Language and cultural background of patients. Knox S (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 52. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Smoking status of adults and their attempts to quit. Valenti L (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 53. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit 2003. Secondary prevention of heart attack or stroke. Harrison C (ed). Sydney: University of Sydney, SAND abstracts from the BEACH program No. 54. URL: <http://pandora.nla.gov.au/tep/14007>.

AIHW GP Statistics and Classification Unit. 2004. Patient weight, perception of weight and weight loss. Charles J (ed). SAND abstracts from the BEACH program No.55. URL <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Prevalence, cause and severity of adverse pharmacological events. Valenti L (ed). SAND abstracts from the BEACH program No. 56. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Prevalence and management of chronic heart failure in general practice patients. Bayram C (ed). SAND abstracts from the BEACH program No. 57. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Lipid lowering medications: patient eligibility under PBS. Miller G (ed). SAND abstracts from the BEACH program No. 58. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Hypertension management and control in general practice patients. Pan Y (ed). SAND abstracts from the BEACH program No. 59. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Prevalence of GORD and associated proton pump inhibitor use. O'Halloran J (ed). SAND abstracts from the BEACH program No. 60. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Prevalence of chronic illnesses identified as National Health Priority Areas among general practice patients. Knox S (ed). SAND abstracts from the BEACH program No. 61. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Use of proton pump inhibitors by general practice patients. Ng A (ed). SAND abstracts from the BEACH program No. 62. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Asthma-prevalence, management and medication side-effects. Henderson J (ed). SAND abstracts from the BEACH program No. 63. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Current use of statins by general practice patients. Pan Y (ed). SAND abstracts from the BEACH program No. 64. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Language and cultural background of general practice patients. Knox S (ed). SAND abstracts from the BEACH program No. 65. <http://pandora.nla.gov.au/tep/14007>

AIHW GP Statistics and Classification Unit. 2004. Anti-psychotic medication use by general practice patients. Britt H (ed). SAND abstracts from the BEACH program No. 66. <http://pandora.nla.gov.au/tep/14007>

ARTICLES IN NON-REFEREED JOURNALS AND OTHER PUBLICATIONS

AIHW GP Statistics and Classification Unit 2005. General practice activity in Australia's states and territories. Charles J (ed). GP Review 9(March).

Britt H 2002. BEACH – Bettering the Evaluation And Care of Health. National Networks (32).

Britt H 2002. The International Classification of Primary Care (ICPC-2 and ICPC-2 Plus). *Coding Matters* 9(June):3.

Britt H 2002. The BEACH Program. *Gpinfonet* 6(6):8.

GP Statistics and Classification Unit 2001. Measures of health and health care delivery in Australia. AIHW Access (July).

Britt H 1999. General practice activity in Australia 1998–1999. *NSW Public Health Bulletin* 10(12):167–169.

AIHW GP Statistics and Classification Unit 2001. Weakness and tiredness as a reason for encounter in general practice. Miller GC (ed). *GP Review* 5(May).

AIHW GP Statistics and Classification Unit 2001. Weighty matters: body mass in general practice patients. Henderson J (ed). *GP Review* 5(Sept).

AIHW GP Statistics and Classification Unit 2001. Severity of illness in general practice patients. Charles J (ed). *GP Review* 5(Oct).

AIHW GP Statistics and Classification Unit 2001. Influenza vaccination in general practice patients. Charles J (ed). *GP Review* 5(Aug).

AIHW GP Statistics and Classification Unit 2001. Smoking and passive smoking in general practice patients. Charles J (ed). *GP Review* 5(Dec).

AIHW GP Statistics and Classification Unit 2001. Anxiety and stress in patients presenting to GPs in Australia. Britt H (ed). *GP Review* 5(April).

AIHW GP Statistics and Classification Unit 2001. Employment status and occupation of general practice patients. Charles J (ed). *GP Review* 5(July).

AIHW GP Statistics and Classification Unit 2002. Gender of the general practitioner. Charles J (ed). *GP Review* 6(Nov).

AIHW GP Statistics and Classification Unit 2002. Measurement of body mass in children attending general practice. Charles J (ed). *GP Review* 6(June).

AIHW GP Statistics and Classification Unit 2002. Referrals. Charles J (ed). *GP Review* 6(April).

AIHW GP Statistics and Classification Unit 2002. Counselling general practice patients. Charles J (ed). *GP Review* 6(May).

AIHW GP Statistics and Classification Unit 2003. Changes over time – NSAID use in general practice. Charles J (ed). *GP Review* 7(Aug).

AIHW GP Statistics and Classification Unit 2003. Changes over time – patient health risk factors. Charles J (ed). *GP Review* 7(Nov).

AIHW GP Statistics and Classification Unit 2004. Changes over time: management of depression in general practice. Charles J (ed). *GP Review* 8(Mar).

AIHW GP Statistics and Classification Unit 2004. Childhood illness and treatment over three decades. Charles J (ed). *GP Review* 8(Sept).

AIHW GP Statistics and Classification Unit 2004. Decrease in prescribing rates – 5 years of BEACH. Charles J (ed). *GP Review* 8(May).

AIHW GP Statistics and Classification Unit 2004. Indigenous Australians at general practice encounters. Charles J (ed). *GP Review* 8(July).